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1. SUMMARY 
 
Zoledronate is a drug that inhibits osteoclastic bone resorption and is commonly 
used to prevent and treat osteoporosis. Recently, due to preclinical evidence of its 
antitumoral properties, there is emerging interest in use of zoledronate as an anticancer 
agent. In view of its high affinity for bone matrix, studies employing in vivo tumor 
models largely addressed the ability of zoledronate to reduce skeletal tumor burden and 
prevent bone metastases. However, whether clinically relevant doses of the drug prevent 
tumor progression in soft tissue tumors and what the corresponding mechanisms of its 
antitumor effects might be, are still areas of investigation. 
To address these issues, immunocompetent mice bearing syngeneic subcutaneous 
tumors were treated with zoledronate at doses equivalent to those recommended for 
humans.  A significant reduction in growth of LLC and MC38 tumors was observed in 
zoledronate-treated mice. Tumors in treated animals showed an increase in apoptotic cell 
death, accounting for the decreased tumor growth rate.  Although several in vitro studies 
have reported a direct pro-apoptotic effect of zoledronate on cancer cells, in vivo 
achievable concentrations of the drug are not cytotoxic to cancer cells. Therefore, we 
examined the effect of zoledronate on the tumor microenvironment, with a focus on 
tumor-infiltrating myeloid cells that are in a privileged position to internalize the drug. 
Surprisingly, flow cytometry analysis revealed an increase in the frequency of CD11b+ 
myeloid cells in the tumors as well as in the spleen, blood and peritoneum of treated 
animals. It has long been recognized that solid tumors actively recruit myeloid cells and 
skew their differentiation toward an immunosuppressive and pro-tumorigenic phenotype, 
the so-called M2-like phenotype that has been implicated in regulating many of the 
“hallmarks of cancer” and thus fostering solid tumor development. Therefore, the 
unexpected inverse correlation between myeloid cell density and tumor growth in 
zoledronate-treated animals prompted us to examine the activation status of these cells in 
treated animals. To this end, tumor-infiltrating myeloid cells were isolated and their 
activation status was assessed by q-PCR analysis of relevant markers of M1 and M2 
activation states. Differential expression analyses revealed that myeloid cells from treated 
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tumors regained an M1-type antitumoral phenotype, showing an increased expression of 
proinflammatory and immunostimulatory mediators such as IL-12, iNOS and IFN-γ and a 
reduced expression of the immunosuppressive factors IL-10, arginase and VEGF. 
Furthermore, these cells displayed an enhanced ability to stimulate CD8+ T cell 
proliferation and IFN-γ production.  
Further characterization of the CD11b+ myeloid cells identified neutrophils as the 
increasingly accumulating myeloid cell type in tumors of zoledronate treated animals. 
Accordingly, treated tumors displayed increased production of the neutrophil-attracting 
chemokines CXCL2/MIP-2 and CXCL5/LIX. To further identify the cellular targets of 
zoledronate action in tumors, two major myeloid subsets, namely CD11b+Ly6G+ 
neutrophils and CD11b+Ly6G- monocytes/macrophages, were sorted and analyzed for 
changes in their immunostimulatory and immunosuppressive properties. Zoledronate 
induced a proinflammatory and antitumorigenic activation profile specifically in the 
neutrophil, but not the macrophage subset of myeloid cells. Study of pharmacological 
inhibition of neutrophils confirmed that neutrophils are essential for the antitumorigenic 
effects of zoledronate, as their depletion renders zoledronate ineffective in restricting 
tumor growth. Another interesting finding was that administration of recombinant TGF-β 
to zoledronate-treated animals reduces the therapeutic efficacy of the drug by impairing 
the increased neutrophil influx in tumor. Accordingly, in simplified cell culture-based 
assays, we showed that TGF-β levels influence the neutrophil chemotaxis towards tumor 
cells derived factors. 
Finally, we attempted to improve the antitumor efficacy of zoledronate by 
encapsulating the drug in liposomes. Liposomal encapsulation significantly improved the 
efficacy of zoledronate by altering its pharmacokinetics and biodistribution profile. 
Collectively, our findings reveal novel antitumorigenic properties of zoledronate 
that may serve as a basis for the design of more effective immunotherapeutic approaches 
against cancer. 
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1. ZUSAMMENFASSUNG 
 
Zoledronat ist ein Wirkstoff der die Knochenresorption durch Osteoklasten 
inhibiert und zur Prävention und Therapie von Osteoporose eingesetzt wird. Neuere 
präklinische Daten zeigen, dass Zoledronat auch als Krebsmittel wirksam ist. Wegen 
seiner hohen Affinität zu Knochengewebe konzentrieren sich die meisten in vivo 
Untersuchungen mit Zoledronat vor allem auf die Reduktion von Knochentumoren und 
Metastasen. Ob jedoch klinisch relevante Dosen von Zoledronat die Bildung von 
Weichteiltumoren verhindern und durch welche Wirkmechanismen Zoledronat das 
Tumorwachstum blockiert ist Gegenstand weiterer Untersuchungen. 
Um diese Fragen zu klären haben wir immunkompetente, tumortragende Mäuse 
mit klinisch relevanten Dosen von Zoledronat behandelt. Dabei resultierte eine 
signifikante Reduktion des Wachstums von subkutan implantierten Lewis 
Lungenkarzinom  und MC38 Kolonkarzinom Tumoren. Behandelte Tumore wiesen 
erhöhte Apoptose auf, was zu reduziertem Tumorwachstum führte. Obwohl verschiedene 
in vitro Studien gezeigt haben, dass Zoledronat einen direkten pro-apoptotischen Effekt 
auf Tumorzellen ausübt, sind die in vivo erreichbaren Konzentrationen nicht zytotoxisch 
auf Tumorzellen. Deshalb untersuchten wir den Effekt von Zoledronat auf die 
Tumormikroumgebung und hauptsächlich auf die Tumor infiltrierenden myeloischen 
Zelltypen, die Zoledronat bevorzugt aufnehmen. Ueberraschenderweise ergab eine 
durchflusszytometrische Analyse, dass die Frequenz von CD11b positiven myeloischen 
Zellen nach Behandlung mit Zoledronat in Tumoren aber auch in der Milz, im Blut und 
im Peritoneum stark erhöht war. Es ist bekannt, dass solide Tumore myeloische Zellen 
aktiv rekrutieren und deren Differenzierung in immunosuppressive und das 
Tumorwachstum fördernde, sogenannte M2-Zelltypen verursachen. Diese Zellen 
regulieren verschiedene Prozesse im Tumorwachstum und sind daher für die Entwicklung 
von soliden Tumoren ausserordentlich wichtig. 
Die unerwartete inverse Korrelation zwischen der Zelldichte der myeloischen 
Zellen und dem Tumorwachstum bei Zoledronat behandelten Tieren bewog uns den 
Aktivierungsstatus dieser Zellen näher zu untersuchen. Dazu wurden tumorinfiltrierende 
                              
ZUSAMMENFASSUNG 
 4
myeloische Zellen isoliert und der Aktivierungsstatus von relevanten M1- und M2-
spezifischen Genprodukten mittels quantitativer Polymerasenkettenreaktionsanalyse 
untersucht. Diese Analyse ergab, dass myeloische Zellen von behandelten Tumoren vom 
M1-Phenotyp waren, mit erhöhter Expression von pro-inflammatorischen und 
immunostimulatorischen Faktoren wie IL-12, iNOS und γ-Interferon, sowie verminderter 
Expression der immunosuppressiven Faktoren IL-10, Arginase und VEGF. Diese Zellen 
hatten auch die Eigenschaft, CD8 positive T-Zellen zu stimulieren und die γ-Interferon 
Produktion zu erhöhen. Die weitere Charakterisierung der CD11b positiven myeloischen 
Zellen identifizierte Neutrophile als der Zelltyp, der in Zoledronat behandelten Tumoren 
angereichert wurde. 
Dementsprechend konnte in behandelten Tumoren eine erhöhte Produktion der 
Neutrophil rekrutierenden Chemokine CXCL2/MIP-2 und CXCL5/LIX nachgewiesen 
werden. Um die zellulären Zielmoleküle von Zoledronat weiter zu identifizieren wurden 
die beiden wichtigsten myeloischen Untergruppen, nämlich die CD11b+Ly6G+ 
Neutrophilen und die CD11b+Ly6G- Monozyten/Makrophagen sortiert und auf ihre 
immunostimulatorischen oder -suppressiven Eigenschaften untersucht. Zoledronat 
induzierte ein pro-inflammatorisches und tumorsuppressives Aktivierungsprofil in den 
Neutrophilen, jedoch nicht in den Monozyten/Makrophagen. Die pharmakologische 
Inhibition der Neutrophilen bestätigte, dass dieser Zelltyp für die antitumor Effekte von 
Zoledronat verantwortlich waren, da ihre Depletion die Wirkung von Zoledronat aufhob. 
Ein weiteres interessantes Resultat war, dass rekombinantes TGF-β den therapeutischen 
Effekt von Zoledronat durch Verminderung der Akkumulation von Neutrophilen ins 
Tumorgewebe aufhob. Entsprechende vereinfachte Experimente in Zellkulturen 
bestätigten, dass TGF-β die Chemotaxis von Neutrophilen zu tumorzellspezifischen 
Faktoren  beeinflusst. 
Schliesslich wurde die antitumor Wirkung von Zoledronat durch Einkapselung in 
Liposomen optimiert. Liposomales Zoledronat war in signifikanter Weise besser 
wirksam, indem dessen pharmakokinetisches Profil verändert wurde. 
Zusammenfassend zeigen unsere Resultate neue Eigenschaften von Zoledronat, 
die die Entwicklung von effektiveren immunotherapeutischen Tumortherapien 
ermöglichen. 
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2. INTRODUCTION 
2.1 Tumor development and heterogeneity in the tumor microenvironment 
Although cancer is a systemic disease, it originates from a single cell harboring a 
mutant DNA sequence that reroutes the crucial pathways regulating survival and death of 
the cell.1  Survival advantaged mutant cells neutralize further homeostatic growth 
constraints and keep proliferating, and continue accumulating other genetic alterations, 
including chromosomal abnormalities and mutations in the sequence of DNA. Due to 
genomic instability and high proliferation rates, each cancer cell has a unique mutational 
signature that gives rise to genetic heterogeneity of a tumor (Figure 2.1).2 For the majority 
of tumors, genetic heterogeneity confers a growth advantage upon cancer cells and this 
heterogeneity is also implicated in the development of drug resistance in cancer therapy.  
This hypothesis has been supported by clinical observations showing that less 
heterogeneous tumors like chronic myeloid leukemia (CML) that are driven by a common 
genetic aberration show better responses to treatment compared to highly heterogeneous 
tumors types like breast and ovarian cancers. 3-5  
 
Figure 2.1: Models of mono-clonal and multi-clonal (heterogeneous) tumor progression. In some 
cancers there is a dominant tumor cell clone that progressively accumulates and inherits similar 
genetic and epigenetic alterations. On the other hand, there could be a predominant clone within 
other types of tumors and there are multiple other clones present as well. Different color circles 
indicate distinct clones. Adapted from Polyak, 2008.6 
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In growing tumors, another type of heterogeneity which provides a growth and 
survival advantage to the cell is developed at the cellular level. As the cancer cells 
proliferate and take up more space, they begin to be restricted by environmental factors 
such as lack of oxygen, nutrients and pressure of the nearby tissue. Without a steady supply 
of nutrition and oxygen, tumors can grow only to a few thousand cells in number or 
measure around 1–2 mm3.7 These microscopic colonies of cancer cells are known as in situ 
tumors (“carcinoma in situ”, CIS) and do not produce any symptoms until they are invading 
the surrounding tissue. Indeed, most people have small, in situ tumors that can remain 
dormant indefinitely.8 To progress further and develop into invasive carcinoma, tumors 
require microenvironmental support. Solid tumors provide this support in their environment 
by forming distinct tissue-like structures mimicking normal tissue structure and function. 
Accumulated clinical evidence, in combination with various mechanistic studies, also 
support the contention that cancer progression mostly depends on the ability of cancer cells 
to hijack and exploit the normal physiological processes of the host. To this end, tumor 
cells send out chemical signals to modulate the different populations of the host's healthy 
cells.9,10 Tumor-derived chemical signals activate genes in the surrounding healthy tissue 
while recruiting blood-derived immune cells simultaneously. As the tumor develops, these 
surrounding and recruited normal cells co-evolve into an activated state through a 
continuous paracrine communication, thereby creating a microenvironment that promotes 
cancer growth and ultimately leads to metastatic disease.11  In this microenvironment, 
cancer cells mainly recruit host blood vessels, co-opt neighboring fibroblasts, and shape the 
local immune response to establish the essential conditions for their survival and success.12 
Thereby, malignant cells create a tolerant neighborhood in which they can function with 
limited interference. Collectively, connective tissue, extracellular matrix, and the resident 
non-cancerous cells surrounding cancer cells are known as tumor stroma. Many researchers 
prefer the broader term “tumor microenvironment,” instead of  “stroma,” as it includes 
infiltrating cells of the immune system (innate and adaptive), and cell-free molecules 
(proteases and growth factors) in addition to the residential stromal components (Figure 
2.2).13 Although the same basic building blocks constitute the stroma of all tumors, the 
actual composition of the tumor microenvironment is quite variable, with differences seen 
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between individuals, between different tumor types, and in different areas of the same 
tumor. Furthermore, the composition of the tumor microenvironment is also altered as the 
disease progresses.14 However, major differences in the stroma of different tumors are 
primarily quantitative. In some desmoplastic tumors, such as many carcinomas of the 
breast, stomach and pancreas, the stroma constitutes up to 90% of the total tumor mass. On 
the other hand, there are tumors such as medullary and lobular carcinomas of the breast and 
many lymphomas in which only minimal stroma is deposited.15  
 
Figure 2.2: Cellular heterogeneity of a tumor. Cancer cells in solid tumors are 
surrounded by a complex microenvironment comprising various cells including endothelial 
cells of the blood and lymphatic circulation, stromal fibroblasts and bone marrow-derived 
cells  including macrophages, myeloid-derived suppressor cells (MDSCs), neutrophils and 
mesenchymal stem cells (MSCs). Adapted from Jabado et al., 2007.16 
 
2.1.1 Significance of the tumor microenvironment in cancer therapy  
 
Early evidences about the effects of the environment on tumor growth were 
provided in 1976 by the work of Solt and Farber demonstrating that growth of a tumor from 
a single mutated cell can only occur when the stromal environment is altered in such a way 
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to allow unrestrained tumor growth.17 In spite of this and many other significant findings, 
cancer research has largely focused for many years on cancer-cell driven carcinogenesis 
with particular emphasis on understanding the mutations causing neoplastic cell 
transformations. Such a cancer cell-centric view of tumor progression largely ignored the 
fact that complex interactions between the cancer cells and stromal cells tightly regulate 
growth of tumors. Partially for this reason, even after decades of implementing treatments 
that selectively target the tumor cell, the survival time for metastatic cancer patients is still 
quite short. Novel strategies are therefore urgently needed to complement and improve 
classical treatments for cancer. In this regard, interactions between cancer cells and their 
host environments offer novel opportunities for therapies based on the improved 
understanding of the nature of these interactions and the mechanisms that govern them. 
Drugs targeting both cancer cells and stromal components are likely to be more effective 
than those directed solely against cancer cells. A potential advantage in targeting the non-
malignant cells of the tumor microenvironment is that these cells tend to be more 
genetically stable than cancer cells, and are therefore less likely to develop resistance to 
therapies.  
Current strategies for cellular, gene, and molecular therapies are focusing on the 
manipulation of the different components of the tumor microenvironment. In this context, 
newly formed blood vessels have been one of the most common targeted components of the 
tumor microenvironment. Various monoclonal antibodies (like bevacizumab; Avastin®)  
and tyrosine kinase inhibitors (like SU5416, PTK787 and Sorafenib) were developed 
against the pro-angiogenic factor vascular endothelial growth factor (VEGF) and VEGF 
receptor signaling, respectively.18 Although angiogenesis inhibitors targeting the VEGF 
signaling pathway have proven to be efficacious in reducing tumor angiogenesis and 
thereby providing a survival benefit in many preclinical cancer models as well as in clinical 
trials,  emerging studies have demonstrated certain drawbacks of these anti-angiogenic 
therapies. The VEGF inhibitors having an initial anti-tumor effect in mouse models of 
pancreatic carcinoma and glioblastoma were found to concomitantly elicit the tumor’s 
adaptation to anti-angiogenic therapy and increase tumor invasion and metastasis as well.19  
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As the most abundant cell types in the stroma of several solid tumors, cancer 
associated fibroblasts (CAFs) were recently brought into focus as valid targets for 
anticancer therapies. These cells produce a variety of growth factors and extracellular 
matrix proteins in turn regulate the growth and progression of carcinoma cells.20 Among 
several potential therapeutic targets of CAFs, fibroblast activation protein (FAP) which is 
specifically overexpressed by the fibroblast in tumor stroma, has long been considered a 
promising anticancer target molecule. Although humanized monoclonal anti-FAP antibody 
(Sibrotuzumab) did not result in disease remission in phase I/II clinical trial for colorectal 
cancer patient21,22, targeting FAP merit further investigation due to recent data providing 
more evidences on the importance of stromal FAP in tumorigenesis.23,24  
Another important group of cells to be targeted in the tumor microenvironment are 
the immune cells. Interactions between immune cells and tumor cells have been of great 
interest because of the possibility that they either restrict tumor progression or actively 
promote tumor growth. Recently, strategies aiming to manipulate the immune cells, 
particularly leukocytes such as regulatory T cells and pro-angiogenic/tolerogenic myeloid 
cells in the tumor microenvironment, have been emerging as potential therapy options. In 
this regard, immunomodulatory compounds like lenalidomide (Revlimid®) that modulate 
both cellular and humoral cells of the immune system and, other biologically important 
targets, have already been approved for the treatment of multiple myeloma and other 
similar lymphoproliferative diseases.25   
To develop better therapeutic strategies targeted at the immune components of the 
tumor microenvironment, it is critical to understand how these cells are altered during 
tumor progression, and how they reciprocally influence tumor initiation and progression. 
Herein, the current understanding of tumor-stroma interaction is reviewed with a particular 
focus on tumor infiltrating leukocytes (TILs), which are the key component of the tumor 
stroma.26 Moreover, the critical effects of targeting these crucial microenvironmental 
players on cancer vascularization, local tumor growth, metastatic spreading and anti-tumor 
immune responses are discussed in the following paragraphs. 
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2.1.2 Leukocytes in the tumor microenvironment 
All tissues are comprised of diverse types of leukocytes, of both innate and adaptive 
lineages, as their normal cellular components. Solid tumors, mimicking the structure of 
normal tissue, also comprise various kinds and amounts of leukocytes depending on type 
and stage of the tumor (Figure 2.3). Leukocytes infiltrating tumors can constitute up to 50% 
of the tumor mass; the majority of these cells are myeloid cells (macrophages, neutrophils, 
dendritic cells, mast cells, eosinophils), as well as B and T lymphocytes.27 Specifically, 
myeloid cells are the major component of the leukocytic infiltrates frequently seen in 
tumors.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Representative sections of human breast and prostate carcinoma tissues depicting 
abundant leukocyte infiltration. Extensive leukocyte infiltration is a typical feature of many 
human cancers. Normal, pre-malignant and malignant tissue sections stained with haematoxylin and 
eosin (H&E) are shown (upper panels of each pair). Immunohistochemical staining for CD45, a 
pan-leucocyte marker, reveals the extent of leukocyte infiltration into pre-malignant and 
malignant stroma (lower, brown stained panels). Coussens et al., 2006.28 
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Infiltration of leukocytes into malignant tissue was first described by the 
distinguished pathologist Rudolf Virchow in 186329; however, only recently we have begun 
to understand the diverse regulatory roles played by leukocytes in tumor growth. 
Originally, the presence of leukocytes in malignant neoplasms was thought to represent the 
host’s immune response to a growing tumor. Yet, solid tumors are mostly recognized as 
“self” and do not evoke effective immune responses capable of eradicating tumors.30,31 In 
contrast, extensive studies in experimental animal models revealed that these cells are 
actively recruited to neoplastic tissues by tumor cells and an abundance of certain types of 
leukocytes is associated with improved tumor progression. A large amount of clinical data 
derived from studies performed on a broad range of solid tumor types has confirmed the 
correlation between high-density leukocytic infiltration, and a poor outcome in patients.32 
Nevertheless in several cancers, the presence of certain types of leukocytes is associated 
with a favorable prognosis. For example, enhanced infiltration of natural-killer cells into 
tumors has been reported to correlate with a good prognosis in human ovarian, colorectal 
and gastric cancers.33,34 Similarly, cytotoxic activation of lymphocytes, particularly CD8+ T 
cells, in response to tumor growth result in tumor regression.35 In sharp contrast, tumor-
activated myeloid leukocytes were shown to restrain the protective function of these cells 
with anti-tumor activity, and subsequently promoted tumor growth and facilitated survival 
of neoplastic cells. Emerging data from clinical and experimental studies suggests that a 
high frequency of tumor-infiltrating lymphocytes are mostly associated with a good 
prognosis; whereas infiltration of myeloid cells correlates with a poor prognosis through 
increased angiogenesis, tissue remodeling, and suppression of anti-tumor immune 
response.36-38 Since myeloid cells have been implicated in the regulation of these crucial 
aspects of tumor physiology, it is of paramount importance to understand how they are 
attracted to the tumor site, how they convey their tumor-promoting effects, and whether it is 
possible to block tumor-promoting activities while concurrently stimulating their anti-
tumorigenic capacity.   
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2.1.2.1 Myeloid cell trafficking within tumor tissue 
Myeloid progenitor cells reside predominantly in the bone marrow.  In normal bone 
marrow, 50% to 60% of cells are dedicated to myeloid cell production. Under certain 
physiological circumstances, myeloid cells are recruited to the site of injury in response to 
wounding or inflammatory stimuli. Mobilization of myeloid cells in bone marrow, and 
recruitment to the site of damage, is mediated by local synthesis of chemokines, cytokines 
and growth factors. (see also 2.1.2.2.1, 2, 3) Throughout the wound-healing process, 
myeloid cells robustly promote healing by fighting infection, stimulating new tissue 
growth, followed by suppressing the response once the situation is resolved. In similar 
manner, these cells are actively recruited into malignant tissues by chemoattractants such as 
VEGF, PlGF, CCL2/MCP-1, CXCL12a/SDF-1α and β-defensins39 and they also regulate 
similar processes to those observed during wound healing. However, due to accumulated 
mutations tumor cells lose the control of positional identity, and keep sending out 
continuous signals that recruit diverse myeloid cell populations to support tumor growth. 
This concept upholds the famous definition of tumors as “wounds that never heal”.29  Not 
only the tumor cells, but also the stromal cells mobilize various subpopulations of bone 
marrow-derived myeloid progenitor cells to the peripheral blood, and ultimately to 
malignant tissue through secretion of cytokines and chemokines (Figure 2.4).  
Surface receptors on myeloid cells are regulated by these chemotactic factors and 
are involved in homing of myeloid cells to tumor tissue. (see also 2.1.2.2.1, 2, 3) This 
process is aided by increased endothelial cell adhesiveness for myeloid cells through 
enhanced expression of adhesion molecules.  
Besides chemokines, concentration of oxygen in the tumor microenvironment also 
indirectly regulates homing of circulating myeloid cells to tissues. Hereof, hypoxia induced 
HIF-1 activity regulates the expression of certain chemoattractants, including MCP-1, CSF-
1, VEGF-A, TNF-α, and SDF-1α.35 These chemoattractant factors do not only regulate the 
recruitment of myeloid cells, but also contribute to initial tumor-specific activation of these 
cells even before their arrival in the tumor. Once recruited into the tumor their function is 
further modulated by the tumor milieu.  
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Figure 2.4: Recruitment of various myeloid linage cell types to the tumor microenvironment 
and their effects on tumor progression. Tumor and stromal cells mobilize diverse subsets of bone 
marrow-derived cells to the peripheral blood through secretion of cytokines and chemokines. 
Subsequently different chemoattractants promote the recruitment and infiltration of these cells to 
the tumor microenvironment where they suppress the anti-tumor immunity or promote tumor 
growth and angiogenesis. Schmid and Varner, 2010. 40 
 
2.1.2.2 Alternative activation of myeloid cells in the tumor microenvironment  
It has become increasingly apparent that tumor progression is closely associated 
with abnormal expansion as well as impaired activation of myeloid cells, especially of the 
macrophages, neutrophils and dendritic cells along with the appearance of a heterogeneous 
set of immunosuppressive, immature myeloid cells called myeloid-derived suppressor cells 
(MDSCs).  Myeloid cells could, in fact, induce an effective anti-tumor immune response by 
directly releasing cytotoxic factors and indirectly presenting antigens to lymphocytes or by 
releasing regulatory molecules to induce anti-tumor activity of T cells. They could also 
activate dendritic cells and natural-killer cells that can possess anti-tumor properties.41  A 
number of in vitro studies have demonstrated the ability of  macrophages to kill tumor cells 
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when appropriately stimulated by lipopolysaccharide (LPS) and interferon-γ (IFN-γ).42 
Consistent with these properties, it was also shown in in vivo models that syngeneic 
macrophages originating from tumor-bearing mice inhibited melanoma growth in nude 
mice more efficiently than the control macrophages.43 Although these findings suggest a 
possible involvement of myeloid cells in anti-tumor response, myeloid lineage cells instead 
drive tumor progression often by promoting cancer cell survival, angiogenesis, 
immunosuppression and metastasis. These effects can partly be explained by the absence of 
environmental stimuli inducing anti-tumorigenic polarization of myeloid cells at the tumor 
site. Instead, following recruitment they are likely to encounter factors that most frequently 
polarize them toward a pro-tumorigenic phenotype. This pro-tumorigenic activation of 
myeloid cells is determined by their interaction with cancer cells, as well as with other 
stromal compartments.  
A variety of inflammatory stimuli can trigger the recruitment and polarization of 
diverse subsets of myeloid cells in tumor tissue. The following sections provide an 
overview of specific pro-tumorigenic myeloid populations, as well as their role in tumor 
progression and considering their crucial and well-documented tumor promoting properties, 
this text will particularly focus on macrophages, neutrophils and bone-marrow derived 
suppressor cells. 
2.1.2.2.1 Macrophages 
Macrophages are a major component of the myeloid infiltrate in a tumor 
microenvironment. Hence, of all cells of the myeloid lineage, they are among the most 
studied and evidenced for their contribution to tumor growth. Blood-circulating monocytes 
are recruited to tumors by tumor-derived chemotactic factors such as M-CSF (macrophage 
colony stimulating factor), CCL2 (chemokine C-C motif ligand 2, MCP-1) and VEGF 
(vascular endothelial growth factor). Upon migrating into the tumor, monocytes 
differentiate into tissue-resident macrophages called tumor-associated macrophages 
(TAMs). The term TAM defines intratumoral localization of macrophages. Macrophages 
are very plastic cells that can adapt a particular phenotype depending on the environmental 
stimuli, and they produce an assorted array of chemokines, cytokines, protesases, 
 
 
INTRODUCTION 
 
 15
angiogenic and growth factors. In response to diverse stimulants in the tumor 
microenvironment, they correspondingly undergo polarized activation. The activation states 
of macrophages, as well as of other myeloid cells, have been defined by a nomenclature 
adapted from the TH1 and TH2 cell response, referred to as M1 (classical) or M2 
(alternative) activation, respectively. Classically activated macrophages (M1) are pro-
inflammatory cells that are stimulated through exposure to factors such as IFN-γ or 
microbial products (like LPS) and possess a markedly enhanced ability to kill pathogens or 
tumor cells.44 In contrast, when TAMs are more exposed to anti-inflammatory molecules, 
such as glucocorticoid hormones, IL-4, IL-13 and IL-10 they are polarized to the opposite 
extreme called M2. They are poor antigen presenting cells (APCs), which support tumor 
growth, angiogenesis, and metastasis, and they suppress the immune system by responding 
to anti-inflammatory cytokines, apoptotic cells and immune complexes. Differential 
cytokine production is a key feature of polarized macrophages. M1 macrophage activation 
in response to microbial products or IFN-γ is characterized by high levels of surface major 
histocompatibility complex class II (MHC-II) expression and antigen presenting capacity; 
high production of pro-inflammatory cytokines such as IL-12, IL-23, IL-1, TNF-α; high 
production of toxic intermediates (nitric oxide (NO)) and reactive oxygen intermediates 
(ROI).45  In contrast, the M2 activation state is characterized by an IL-10high and IL-12low 
phenotype; expression of low levels of MHC-II and increased production of angiogenic 
factors and anti-inflammatory cytokines like IL-10, arginase and TGF-β. Furthermore, M1 
macrophages express opsonic receptors (e.g., FcγRIII), whereas M2 macrophages express 
preferentially non-opsonic receptors (e.g., scavenger receptors like mannose receptors and 
CD163).44 A comprehensive representation of the polarized functions of macrophages is 
shown in Figure 2.5.  
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Figure 2.5: Polarization of macrophage function. Monocytes differentiate into polarized 
macrophages when exposed to diverse stimuli. In the presence of IFN-γ; granulocyte macrophage-
colony stimulating factor (GM-CSF), LPS and other bacterial products, monocytes differentiate into 
M1-polarized cells eliciting microbicidal activity, immunostimulatory functions, and tumor 
cytotoxicity by producing TNF-α, IL-12, reactive nitrogen, and oxygen intermediates. On the other 
hand, when monocytes differentiate in the presence of IL-4, IL-13, IL-10 or corticosteroids, they 
mature into M2 macrophages that are involved in repair and remodeling of tissue, angiogenesis and 
tumor progression. Scholar et al.,2007 (modified).46 
 
Due to the cytokine milieu of the tumor microenvironment, TAMs generally have a 
phenotype and function similar to M2 macrophages. They express high levels of M2 
macrophage markers (IL-10, TGF-β, ARG1, CD163 and the mannose receptor) and low 
levels of mediators of M1 macrophage-mediated inflammation (IL-12, iNOS, TNF-α, and 
IL-6).47 Still, this discrimination between M1 and M2 macrophages is rather a simplified 
view of these two extremes of polarization; it does not fully represent the continuum of 
functional states of macrophages in the tumor microenvironment.  
Analysis of the molecular basis of the TAM phenotype identified components of the 
NF-κB signaling system as one of the main players in the modulation of macrophage 
function. Recently, Hagemann et al. revealed the requirement for IKKβ to maintain the M2 
phenotype of TAMs in a mouse model of ovarian cancer.48 Correspondingly, NF-κB 
inhibition by targeted deletion of IKK-β in TAMs increased their anti-tumor activity 
through reduced production of arginase-1, IL-10, TNF-α, as well as increased production of 
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inducible nitric oxide synthase (iNOS) and IL-12. These data suggest that IKKβ signaling 
in macrophages maintains their alternative tumor-promoting phenotype.48 On the contrary, 
in tumors at a more advanced stage of progression, a therapeutic effect was achieved 
through the restoration of NF-κB activity in myeloid cells.49,50 These divergent results may 
be associated with dynamic changes in a tumor microenvironment during transition from 
early neoplastic events towards advance stages. These changes may result in progressive 
modulation of NF-κB activity in tumor-infiltrating macrophages. Other important 
modulators of macrophage polarization are certain members of the STAT family of 
transcription factors.  Although earlier evidence indicated  that the STAT1 activation 
regulates the M1 activation of macrophages, recent reports argue against this, and suggest 
that STAT1 activation may induce TAM-mediated suppressive activity and tumor 
progression.51-53 In addition, STAT3 and STAT6 activation were also shown to be 
associated with M2 macrophage polarization.54,55 
2.1.2.2.2 Neutrophils 
Neutrophils are short-lived white blood cells derived from bone marrow myeloid 
progenitors. During infection related immune responses, neutrophils are usually the first 
cells to arrive at the scene of infection, where they release chemokines and proteases that 
can, in turn, recruit both innate and adaptive immune effector cells. Neutrophils can also 
release several cytotoxic mediators, including reactive oxygen species, membrane-
perforating agents, proteases and soluble mediators such as IFNs, TNF-α and IL-1β, 
suggesting their potential anti-tumor activity. Thus, they are considered as potential anti-
tumor cells.56 Though, this does not appear to be the case in cancer, and the role they play 
in tumors is still controversial. Low numbers of neutrophils are found in most of human 
tumors. Both cancer cells and stromal compartments of a tumor actively recruit neutrophils 
by means of secreted chemotactic factors, in particular G-CSF, GM-CSF, CXCL2/MIP-2α 
(functional homolog of human IL-8), CCL3/MIP-1α, CXCL5/LIX and CXCL1/KC. Upon 
being recruited to the tumor site, neutrophils can be tumor growth-stimulatory or -tolerant. 
An increased density of tumor-infiltrating neutrophils was found to correlate with a poor 
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prognosis in patients with adenocarcinoma and metastatic melanoma; whereas neutrophil 
infiltration in few cases like gastric carcinoma was linked to a good prognosis.57-59 This 
discrepancy is probably related with the degree of recruitment and the differential 
activation of neutrophils, depending on the intratumoral cytokine microenvironment in 
which they act. Similar to TAMs, the functional status of tumor associated neutrophils 
(TANs) evidently governs their ability to express an anti-tumor potential. Accumulating 
experimental and clinical evidence also confirms that neutrophils can polarize in a type I or 
type II direction in tumors. Recently, Fridlender et al. characterized N1 and N2 polarized 
phenotypes of TANs, similar as described for TAMs. In lung and mesothelioma cancer 
models, TANs were shown to acquire a pro-tumor phenotype (N2). The pro-tumor 
activities of N2 TANs include the production of more immunosuppressive cytokines and 
reduced cytotoxic activity in vitro. This pro-tumor phenotype of neutrophils was found to 
be induced and maintained by TGF-β (Figure 6).60 This finding is further supported by 
previous data indicating that TGF-β can inhibit neutrophil activity and cytotoxicity in 
vitro.61 Also, a systemic blockade of TGF-β skewed the neutrophil differentiation toward 
the N1 phenotype that is characterized by the expression of more immunoactivating 
cytokines, lower levels of arginase and a higher capability of killing tumor cells in vitro. N1 
polarized neutrophils execute anti-tumor activities indirectly as well, by promoting 
recruitment and activation of CD8+ T cells (Figure 2.6). In addition to inducing the anti-
tumor (N1) polarization, blocking of the TGF-β pathway led to increased recruitment of 
Ly6G+ neutrophils in tumors.60 This finding is consistent with previous studies 
demonstrating an enhanced influx of myeloid cells into mammary carcinomas deficient in 
type II TGF-β receptor.62 In a parallel study, it was shown that abrogation of the TGF-β 
signaling in human breast cancer cells enhances the production of the neutrophil 
chemoattractants CXCL1 and CXCL5.63 Apparently, TGF-β is one of the major players in 
regulating neutrophil recruitment and activation in the tumor microenvironment. A recent 
study by Weiss et al. suggested another factor that could influence neutrophil recruitment 
and differentiation in tumors. These authors reported that constitutive expression of IFN-β 
counteracts cancer-supportive function of neutrophils by inhibiting expression of genes 
encoding pro-angiogenic and homing factors in these cells. In this frame, IFN-β deficient 
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mice exhibited enhanced growth of melanoma accompanied by higher infiltration of 
neutrophils with pro-tumor properties.64 
 
Figure 2.6: The proposed TGF-β 
mediated pro-tumorigenic 
polarization of neutrophils in the 
progression of tumors.  Inhibition of 
TGF-β activity leads to the 
differentiation of neutrophils to anti-
tumor N1 cells. While N2 cells inhibit 
the cytotoxic response of CD8 T cells, 
N1 cells enhance the anti-tumor action 
of CD8+ T cells. The microphotograph 
depicts neutrophils (arrows) closely 
associated with carcinoma cells. 
Adapted from Hofman, 2010.65
Many other studies demonstrated that tumor-infiltrating neutrophils have an N2 
phenotype that contributes to tumor progression and immunosupression.64,66-68 Yet, when 
appropriately stimulated, these cells hold the potential to shift the tumor-leukocyte 
relationship toward tumor rejection.    
2.1.2.2.3 Myeloid-Derived Suppressor Cells 
Myeloid derived suppressor cells (MDSCs) are another well-described population 
of tumor-infiltrating myeloid cells that have been shown to exert a negative effect on the 
anti-tumor immune response. MDSCs are a heterogeneous population of cells comprised of 
monocyte, granulocyte, dendritic cell precursors and myeloid cells at an early stage of 
differentiation.69,70 These cells are defined by the co-expression of monocytic marker 
CD11b and granulocyte differentiation antigen Gr1 (constituted by the two epitopes Ly6C 
and Ly6G). Recent studies broadly defined two major subsets of MDSC: cells of 
granulocytic (CD11b+Ly6G+Ly6Clow) and monocytic (CD11b+Ly6G-Ly6Chigh) 
phenotype.71,72  
It has been well established that the frequency of these cells significantly increases 
in the spleen and bone marrow of tumor-bearing mice, as well as in the peripheral blood 
and tumors of cancer patients. In naive tumor-free mice, MDSCs constitute ∼30% of all 
bone marrow cells and ∼3% of all nucleated splenocytes. However, they may represent 
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more than 20% of all splenocytes in tumor bearing mice.73 In both patients and 
experimental animals, MDSCs have been shown to be mobilized from bone marrow in 
response to multiple tumor-derived factors such as Bv8 and endocrine gland-derived VEGF 
(EG-VEGF).66,74 Their recruitment into the tumor site is then mediated by chemotactic 
factors like CCL2/MCP-1, CXCL12/SDF-1α, CXCL5 and KIT ligand.75  Although they are 
able to differentiate into mature myeloid cells upon expose to appropriate stimuli, their 
differentiation is blocked under tumor cell conditioned media in vitro or in a tumor-bearing 
host in vivo.76 These immature myeloid cells potently suppress maturation and anti-tumor 
activation of dendritic cells, T cells and natural killer cells, a phenotype that currently 
provides the most effective way of identifying MDSC.77 Hence, injection of tumor cells in 
combination with CD11b+Gr1+ cells prompt tumor growth.62 Accordingly, depletion of 
Gr1+ cells in tumor-bearing mice leads to delayed tumor growth, suggesting MDSC as 
potential targets of anti-cancer therapy.78 
Many reports have indicated that CD11b+Gr1+ cells from naive tumor-free mice are 
not immune suppressive.72 However, it has not yet been uncovered why CD11b+Gr1+ cells 
derived from tumor-free and tumor-bearing animals exhibit different functions. Even in the 
same tumor-bearing mice, MDSCs isolated from the tumor site and from peripheral 
lymphoid organs display profound functional differences. In a recent study, Gabrilovich et 
al. suggested a HIF-1α mediated regulatory mechanism for the biological dichotomy 
displayed by MDSCs within the tumor microenvironment. These researchers demonstrated 
that MDSCs in the spleen of tumor bearing animals cause ROS mediated antigen-specific T 
cell unresponsiveness. On the other hand intratumoral MDSCs with similar morphology 
and phenotype suppress both antigen specific and nonspecific T cell function through an 
elevated level of NO and arginase I production. HIF-1α was found to be responsible for the 
altered functions of MDSC in the tumor microenvironment.79  
2.1.2.3 Role of myeloid cells in tumor growth and metastatic spread 
Due to their remarkable plasticity and capacity to produce a wide range of cytokines 
and chemokines, tumor-educated myeloid cells are the key regulators of tumor progression. 
Dense myeloid infiltration sites adjacent to areas of basement membrane breakdown and 
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tumor invasion are found in many tumor types.36,80 Many other studies have documented a 
positive correlation between the number of myeloid cells and a poor prognosis.28,39 Beyond 
that, genetic elimination and depletion of myeloid cells in animal tumor models were 
shown to impair tumor progression by altering various physiological processes that are 
necessary for tumor development.81,82 These studies, as well as many others, have clearly 
demonstrated that many physiological processes that are critical to tumor development, 
such as cancer cell survival, angiogenesis, tissue remodeling, metastasis and immune 
suppression, are tightly regulated by myeloid infiltrates in the neoplastic environment.  
2.1.2.3.1 Regulation of angiogenesis 
As one of the hallmarks of cancer, angiogenesis is a very critical process for 
providing the necessary nutrients, oxygen and removal of waste products, as well as 
providing an escape route for metastasizing tumor cells.83 Tumors at a size of 1-2 mm3 alter 
their angiogenic phenotype to support continuous proliferation of endothelial cells.83 
Although various studies demonstrated that highly metastatic cell lines produce elevated 
levels of pro-angiogenic factors, tumor angiogenesis is likely initially stimulated by 
activated myeloid cells recruited into neoplastic tissue.84  
Production of VEGF is one mechanism by which tumor infiltrating myeloid cells 
trigger and increase angiogenesis and foster tumor development. VEGF functions as a 
survival factor for endothelial cells, and induces angiogenesis by stimulating recruitment 
and proliferation of endothelial cells.85 TAMs accumulate in poorly vascularized hypoxic or 
necrotic areas and respond to hypoxia by increasing the release of VEGF along with a 
number of other pro-angiogenic factors including TNF-α, fibroblast growth factor-2 (FGF-
2), platelet derived growth factor (PDGF), urokinase-type plasminogen activator (uPA) and 
MMPs.86,87 Hypoxic conditions in tumors stimulate expression of these pro-angiogenic 
molecules by activating hypoxia-inducible factors (HIFs) in macrophages. Activated 
macrophages also release nitric oxide (NO), a molecule that provokes increased vascular 
flow.88 Lin and Pollard demonstrated that in the PyMT mouse model of mammary 
carcinogenesis, macrophages are recruited to pre-malignant tumors immediately before 
onset of the angiogenic switch that precedes the transition to a malignant phenotype. 
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Genetic ablation of macrophage infiltration into the neoplastic tissue delayed the 
angiogenic switch and tumor progression, whereas genetic restoration of the macrophage 
infiltration in these tumors rescued the vessel phenotype (Figure 2.7).89  
Another myeloid population implicated in tumor angiogenesis are the MDSCs. 
Tumor-educated MDSC express elevated levels of the matrix degrading enzyme MMP-9 
that triggers VEGF release from the extracellular matrix (ECM), which then induces 
proliferation of endothelial cells.90,91 Interestingly, some tumors are resistant to anti-
angiogenic blockage by VEGF antibodies.92 A study by Shojaei et al. revealed that these 
refractory tumors were infiltrated with a higher frequency of CD11b+Gr1+ myeloid cells 
compared to sensitive tumors. These researchers further demonstrated that accumulation of 
CD11b+Gr1+ cells in tumors renders them refractory to anti-VEGF therapy, (most) likely 
because they are modulated by refractory tumor cells to produce alternative factors that can 
promote angiogenesis independently of VEGF. Finally, antibody mediated depletion of 
myeloid cells rendered the refractory tumors responsive to anti-VEGF therapy.93  
Like other pro-angiogenic myeloid populations, tumor associated neutrophils have 
also been reported to support tumor growth by producing pro-angiogenic factors such as 
VEGF, IL-8 and certain proteases including  MMPs and elastase.94-96 Indeed, neutrophil-
derived VEGF not only stimulates the migration and proliferation of endothelial cells, but 
also induces an elevated IL-8 secretion by endothelial cells, thereby enhancing further 
recruitment of VEGF-producing neutrophils.97 This paracrine feed-forward mechanism was 
thought to enhance the angiogenic response by neutrophils. It is intriguing how neutrophils 
play a critical role in activating tumor angiogenesis in spite of their low abundance. For 
instance, neutrophils variably constitute 0.1–0.4 % of the total cells of solid tumors in a 
mouse model of pancreatic islet tumorigenesis (RIP1-Tag2). Nevertheless, systemic 
ablation of these cells during the early stage of tumor development significantly reduced 
the frequency of angiogenic switching.98  These data support the hypothesis that the scarce 
neutrophils are the key initial source of MMP-9 that triggers the angiogenic switch through 
activation and release of latent VEGF. This significant effect of neutrophils might be 
partially explained with their critical localization at the interface between tumor and 
endothelial cells, as well as with their ability to produce crucial rate-limiting molecules.  
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The importance of myeloid cells in promoting tumor angiogenesis has been well 
investigated. Even so, the underlying molecular mechanisms remain to be fully explored. In 
this scope, Kujawski et al. reported that STAT3 activation in tumor-associated myeloid 
cells is critical for tumor angiogenesis. They identified that elevated STAT3 activity in 
TAMs and MDSCs up-regulated the expression of STAT3 pro-angiogenic target genes 
such as VEGF, MMPs and bFGF. Consequently, pro-angiogenic activity of myeloid cells 
was abolished when STAT3 was ablated in these cells. 99 
 
   
 
Figure 2.7: Myeloid cells promote angiogenesis in the tumor microenvironment. A.Malignant 
and stromal cell derived chemoattractants induce the infiltration of myeloid cells from the 
circulation into the tumor microenvironment. Some chemoattractants are also upregulated by cells 
in hypoxic and necrotic regions of tumor and may also attract certain types of myeloid cells into 
these regions. B.Following entry into tumor tissue, MDSC and TAMs accumulating in hypoxic sites 
release pro-angiogenic factors. These cells, along with neutrophils throughout the tumor also secrete 
MMP-9 and bio-active VEGF, which then induce angiogenesis. Moreover, contact of TAMs with 
MDSC causes TAMs to downregulate the anti-angiogenic factor IL-12 and MDSC to upregulate IL-
10. A subset of macrophages, the TIE2-expressing monocytes (TEM) secrete angiogenic factors. 
MDSC were shown to be capable of trans-differentiating into endothelial-like cells in vitro and that 
they may become incorporated into new blood vessels in tumors. Adapted from Murdoch et al., 
2008.100 
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2.1.2.3.2 Regulation of tumor growth and survival 
Beyond activating vascularization, tumor-infiltrating myeloid cells can also promote 
neoplastic growth by creating a microenvironment that is rich in growth factors and 
cytokines that can stimulate proliferation and survival of neoplastic cells.101  Growth-
promoting effects of various myeloid cell-derived cytokines were shown in different tumor 
models like IL-6 in hepatocellular carcinoma,102,103  TNF-α104 and IL-6105 in colitis 
associated cancers. Other growth factors specifically secreted by TAMs have also been 
implicated in tumor growth: epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF).75,106 
Accumulating data for solid tumors conveyed a correlation between TAM infiltration and 
tumor cell proliferation.107,108 
  Besides directly promoting tumor cell proliferation, tumor-educated myeloid cells 
can also indirectly facilitate tumor growth through suppression of anti-tumor immune 
responses, allowing the tumor escape from immune surveillance. Different mechanisms 
have been suggested for the immunosuppressive effects of myeloid cells, such as secretion 
of immunosuppressive cytokines, generation of reactive oxygen species (ROSs) and 
increased activity of arginase and nitric oxide (NO). MDSCs are thought to play a major 
role in preventing the immune system from attacking tumor cells. In recent years, they have 
been shown to suppress the immune system through multiple mechanisms, including 
inhibition of T cell activation by direct cell to cell contact, by production of immuno-
suppressive mediators, and also by inducing regulatory T cells (Treg).73,109,110 One 
important immunosuppressive mediator that is highly produced by the MDSC is arginase, 
which causes a reduction in the arginine necessary for T cell activation.111 Another MDSC-
derived immunosuppressive mediator, TGF-β, also converts naive CD4+ T cells into 
adaptive Tregs.112  
Normally, macrophages from healthy individuals bear the potential to lyse tumor 
cells and present tumor-associated antigens and thereby activate the anti-tumor response of 
T cells and NK cells. In contrast, tumor-educated macrophages act oppositely and inhibit 
anti-tumor response through several mechanisms. Initially, they are limited in their ability 
 
 
INTRODUCTION 
 
 25
to present tumor associated antigens to T cells due to the presence of tumor derived factors 
such as IL-10, TGF-β1 and PGE2 suppressing the expression of MHC class II molecules. In 
turn, they themselves produce IL-10, TGF-β and PGE2 that contribute to suppression of the 
cytotoxic T cell response.113,114  Not only the intratumoral macrophages, but also spleen and 
peritoneal macrophages of tumor-bearing individuals share these similar 
immunosuppressive properties.115 Next, TAMs were also shown to foster a tumor’s 
immune privilege by attracting CD4+CD25+FOXP3+ Tregs that are known to suppress the 
anti-tumor function of cytotoxic T cells. Accumulation of Tregs in tumors is a common 
feature of human cancers and the abundance, as well as suppressor activities of these cells, 
were found to be highly correlated with a poor prognosis.116 Using ovarian carcinoma 
samples from human patients, Curiel at al. revealed that TAMs regulate Treg trafficking to 
tumors by producing CCL22, a chemokine that mediates regulatory T cell recruitment.117  
The pioneering work of Fridlender et al. demonstrated that N2 polarized neutrophils 
control the activation status of CD8 cells in the tumor microenvironment. Comparatively, 
tumor infiltrating CD8 cells can also control the activation and migration of tumor-
associated neutrophils.60,118 Finally, the release of reactive oxygen species, i.e., H2O2, 
during the oxidative burst of tumor-activated neutrophils has been suggested to be the 
underlying mechanism of  systemic T-cell dysfunction in advanced cancer patients.68 
 
2.1.2.3.3 Regulation of invasion and metastasis 
 
Originally, the ability of a tumor to undergo invasion and to metastasize in a 
specific organ was thought to be highly cancer cell specific. However, recent findings have 
challenged this notion. Myeloid cells were found to be critically contributing to those steps 
of tumor progression by producing several factors which enhance tumor cell invasion and 
metastasis. One of the main mechanisms by which these cells support tumor metastasis is 
the production of enzymes such as MMPs, plasmin and urokinase type plasminogen 
activator (uPA) which regulate the digestion of extracellular matrix, thus favoring tumor 
cell invasion. Direct evidence has shown that MMP-9 supplied by myeloid subsets like 
macrophages, neutrophils and mast cells, increase the incidence of invasive epidermis 
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cancer in a mouse model of multi-stage tumorigenesis.119 The critical role of myeloid cells 
in tumor metastasis was also confirmed by mouse tumor models in which myeloid cells 
were either genetically or pharmaceutically ablated. In a mouse mammary cancer model, 
Lin et al. reported that the absence of CSF-1, a macrophage growth factor, significantly 
blocked intratumoral infiltration of macrophages, and consequently delayed both the tumor 
progression to malignancy and metastatic spread to the lung. Furthermore, restoration of the 
expression of CSF-1, specifically in the mammary epithelium of null mutant mice, reverses 
the phenotype and accelerates both tumor progression and metastasis.81 Neutrophils in 
tumor microenvironments were also reported to be critical for the acquisition of a 
metastatic phenotype.  In a murine fibrosarcoma model, they have been shown to promote 
the poorly tumorigenic tumor cells to acquire an aggressive metastatic phenotype. Genetic 
and chemical ablation of neutrophil infiltration dramatically suppressed the metastatic 
phenotype of tumors as compared with those in control mice.67   
Recent evidence suggests another interesting concept: Primary tumors are able to 
modify the distant sites prior to the arrival of metastatic cells to create a permissive 
microenvironment, a so-called “pre-metastatic niche”.120 Bone marrow derived myeloid 
cells are thought to be major executers of this process.121,122 In a pioneering study which 
attempted to investigate the molecular mechanism of tissue-specific metastasis, Hiratsuka 
and colleagues showed that MMP-9 is specifically induced in pre-metastatic lung 
endothelial cells and macrophages by distant primary tumors, suggesting that it 
significantly promotes lung metastasis.123 A later report by Kaplan et al. supported those 
findings and further showed that VEGFR1+ bone marrow-derived hematopoietic progenitor 
cells home to tumor-specific pre-metastatic sites and establish cellular clusters before the 
arrival of tumor cells.121 These clusters alter the microenvironment by MMP-9 production 
and enhanced expression of SDF-1 creating a chemokine gradient that permits the attraction 
of tumor cells and their incorporation into the niche. Afterwards, Hiratsuka et al. further 
reported that primary tumor-mediated attraction of Mac 1+ (macrophage antigen 1)-myeloid 
cells to the pre-metastatic lungs induces the colonization of the lung by tumor cells. 
Secretion of certain factors like, TGF-β, TNF-α, and VEGF-A by the primary tumor 
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stimulates expression of the inflammatory chemoattractants S100A8 and S100A9, which in 
turn attract CD11b+ (Mac 1+) myeloid cells to the pre-metastatic milieu.122   
 In short, all these studies provided evidence that the different myeloid subsets alter 
the pre-metastatic lung environment, making it easier for tumor cells to extravasate from 
blood vessels and to colonize the lung. 
2.1.3 Modulation of myeloid cells in the tumor microenvironment: a new prospect in 
cancer therapy 
Based on a vast amount of clinical and pre-clinical evidence, current knowledge 
clearly suggest that therapeutic targeting not only of the cancer cells, but also of the 
microenvironment is necessary for an effective inhibition of tumor growth. As a result, 
interference with the microenvironmental growth support is becoming more widely 
appreciated as an attractive therapeutic strategy. As a key component of the tumor 
microenvironment, tumor promoting properties of myeloid cells define these cells as 
valuable targets for therapeutic interventions. To this end, depletion of myeloid cells may 
increase the therapeutic benefit, and perhaps prevent metastatic progression, but it also 
results in prolonged suppression of innate immunity. Since they are critical mediators of 
host defense against infections, depletion of myeloid cells may not be feasible in human 
patients. Furthermore, the same myeloid cells have the potential to elicit an anti-tumor 
immune response, and suppress the malignant progression, if appropriately stimulated. 
However, attempts to stimulate the immune system to mount an effective anti-tumor 
response mostly aimed to utilize T-cell based strategies. Although the significance of MHC 
class I-restricted cytotoxic T lymphocytes (CTLs) as effectors of anti-tumor immunity has 
been widely demonstrated, most human tumors lack MHC class I expression, or are so 
inadequately differentiated and poorly immunogenic that success of T-cell based tumor-
specific immunotherapy is rather limited.42,124-126 Effective host anti-tumor reactivity could 
better be implemented by cells of innate immunity, such as macrophages, NK cells, and 
granulocytes. Difficulties raised by the recognition of specific tumor-associated antigens, 
and due to absent and defective MHC-class I antigen expression, are thus evaded. 
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With this in mind, it might be possible to develop novel strategies aimed at re-
programming tumor associated myeloid cells in favor of an anti-tumor phenotype. Based on 
the M1 versus M2 paradigm of macrophage polarization, inhibition of M2 and activation of 
M1-inducing signals was suggested as a potential strategy to re-establish the anti-tumor 
function of macrophages.127 Indeed, accumulating evidence has indicated that 
pharmacological skewing of macrophage polarization, from M2 to M1 phenotype, is able to 
maintain an anti-tumor activity. For example, in a study with different tumor models, 
Guiducci et al. tested the hypothesis whether the treatment of tumor-bearing mice with a 
macrophage chemoattractant would synergize with a treatment that would simultaneously 
switch the macrophage phenotype from M2 to M1. Administration of macrophage 
chemoattractant CCL16, in combination with a microbial stimulus (CpG oligonucleotide, a 
Toll-like receptor-9 ligand), and an anti-IL-10 receptor antibody was shown to promptly 
skew the tumor-infiltrating macrophage phenotype from M2 to M1 that triggered an innate 
response regressing pre-established large tumors.128 Considering their central role in the 
polarization of myeloid cell functions, members of the STAT family of transcription factors 
are valuable targets for the modulation of myeloid cells. Activation or inactivation of 
specific STATs is, therefore, a potential strategy to restore the anti-tumoral function of 
myeloid cells. A representative example is provided by the work of Rosenberg et al. 
wherein TAMs from mammary tumor bearing STAT6-/- mice were shown to display an M1 
phenotype, characterized with low level expression of ARG1 and high level expression of 
NOS2.129 STAT6-/- mice with M1 macrophages were also shown to reject spontaneous 4T1 
mammary carcinoma.130 In the same line, Rauh and colleagues demonstrated the critical 
role of another factor, SHIP1 phosphatase, in programming macrophage M1 versus M2 
functions. Mice deficient in SHIP1 displayed a skewed development toward M2 
macrophages, and thus pharmacological modulators of this phosphatase are under 
investigation.131 More recently, a host-derived factor, histidine-rich glycoprotein (HRG) 
was reported to promote M1 polarization of TAMs. It was shown that HRG induced M1 
macrophage-mediated anti-tumor immune response and vessel normalization that 
subsequently inhibited tumor growth and metastasis, while improving chemotherapy.132  
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 To date, the anti-tumor potential of neutrophils has received little attention, and 
scientists have not yet fully considered the possibility of utilizing their functions as 
effective weapons against cancer. Yet, compelling evidence recently gathered signifies that 
under appropriate stimulation neutrophils reveal very powerful tumor-inhibitory properties. 
The functional status of a granulocyte evidently governs its ability to express its anti-tumor 
potential. As neutrophils in tumor-bearing individuals have impaired cytotoxic activity, the 
elaboration of systems capable of stimulating the recruitment of neutrophils, and their anti-
tumorigenic activation within a tumor microenvironment can be suggested as a new 
therapeutic approach. Such an approach has been tested in a number of settings. Early 
studies with mammary adenocarcinoma cells transfected with cytokine and chemokine 
genes, and injected into syngeneic mice, indicated that nonspecific mechanisms, mostly 
supported by neutrophil function, have much greater therapeutic power than those elicited 
by specific immunity.133-135 In particular, local or systemic administration of rIL-12 in mice 
bearing subcutaneous mammary carcinoma resulted in a rapid influx of neutrophils with 
high destructive potential and anti-angiogenic function.136 Finally, TGF-β has been defined 
as a major regulator of neutrophil’s functional status. Specifically in tumors, TGF-β has 
been noted to drive pro-tumorigenic polarization of neutrophils. Along these lines, 
inhibition of TGF-β signaling offers a means to manipulate neutrophil polarization in vivo 
that can shift the tumor/neutrophil relationship toward tumor inhibition. As mentioned in 
section 2.1.2.2.2, TGF-β receptor blockage in tumor bearing mice was shown to induce the 
activation of CD11b+Ly6G+ neutrophils with an anti-tumorigenic phenotype that resulted in 
a significant tumor growth delay.60  
Together, all these findings indicate the significance of re-programming myeloid 
cell phenotypes to affect tumor outcome and, accordingly, suggest it as a promising 
strategy to complement the established anticancer treatments. The major question that 
arises with regard to this capability then becomes what are the potential endogenous or 
environmental factors that could modulate the state of activation of these myeloid cells and 
what are the cellular and molecular mechanisms through which these factors regulate the 
modulation?  
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In this context, the following section provides an overview of bisphosphonates, a 
class of drugs that might have potential immune-modulatory properties on innate cells in 
cancer. Their pharmacological properties and documented anti-tumor activities are given 
with a special emphasis on zoledronate that is a new generation bisphosphonate and the 
focus of this study.  
 
2.2 Bisphosphonates  
2.2.1 General properties of bisphosphonates  
Bisphosphonates (BPs) are inorganic pyrophosphate analogs (PPi) that effectively 
inhibit osteoclastic bone resorption and, accordingly, are widely used in medicine to treat 
metabolic bone diseases, such as postmenopausal osteoporosis,137  Paget's disease,138 tumor 
associated osteolysis,139 and more recently to prevent bone metastasis. 140 The high affinity 
of the bisphosphonates for the calcium component of the bone matrix (hydroxyapatite) is 
the origin of the bone-specificity of these compounds. In vivo organ distribution studies 
demonstrated that bisphosphonates are mainly localized in newly formed bones and 
subsequently internalized by cells involved in bone resorption, namely osteoclasts where 
they inhibit their activity.141 Because osteoclasts are highly endocytic cells, 
bisphosphonates released from degraded bone matrix are likely to be taken up by 
osteoclasts through endocytosis, thereby affecting them directly. Nevertheless, this does not 
exclude the possibility that small amounts of these drugs are internalized by adjacent cells 
(such as osteoblasts, bone marrow cells, or tumor cells in case of bone tumors). Due to their 
high affinity for bone matrix, systemic availability of bisphosphonates is rather low with 
the exception of a transient raise of plasma levels in the post-administration period.142 
Based on their chemical structure bisphosphonates can be divided into two distinct 
pharmacological classes; nitrogen-containing bisphosphonates, (N-BPs, e.g. zoledronate) 
and non-nitrogen containing bisphosphonates (non-N-BPs, e.g. clodronate), which more 
closely resemble PPi. Pyrophosphate has a P–O–P structure, two phosphate groups linked 
by an oxygen atom. Bisphosphonates have a P–C–P structure, where the central oxygen 
atom is replaced by a carbon atom. As shown in Figure 2.8, the first generation 
bisphosphonate, clodronate has R1 and R2 side chains with two chlorine atoms attached to 
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the central carbon atom, whereas the new generation bisphosphonate zoledronate (1-
Hydroxy-2-(imidazol-1-yl-amino) ethylidene-1,1-bisphosphonic acid) has a R1 side-chain 
with a hydroxyl group and an R2 side-chain with a imidazolyl group, that strongly 
influence bone binding and anti-resorptive properties. Bisphosphonates containing nitrogen 
atoms in the R2 side-chain like zoledronate are more potent than non-nitrogen 
bisphosphonates.142                                                           
 
Figure 2.8:  The chemical 
structure of pyrophosphates, 
generic bisphosphonates, 
clodronate and zoledronate. 
Pyrophosphate has two phosphate 
groups linked by an oxygen atom.  
Zoledronate contains a tertiary amine 
within an imidazole ring, making 
zoledronate one of the most potent 
available bisphosphonate to date.
 
2.2.2 Molecular mechanism of bisphosphonate activity 
The molecular mechanism of the bisphosphonates differs according to their 
chemical structure. After cellular uptake, non-nitrogen-containing bisphosphonates (e.g., 
clodronate) are metabolized to cytotoxic analogs of adenosine triphosphate (ATP). 
Accumulation of cytotoxic ATP analogs in the cell cytoplasm directly causes apoptosis 
by inhibiting mitochondrial adenine nucleotide translocase (ANT).143 On the other side, 
the more potent nitrogen-containing bisphosphonates exert their effects mainly by 
inhibiting a key enzyme in the mevalonate pathway, farnesyl pyrophosphate synthase 
(FPP synthase, Figure 2.9), thereby preventing the synthesis of isoprenoid compounds 
that are essential for the posttranslational modification (e.g. prenylation) of small 
guanosine triphosphate (GTP)-binding proteins (small GTPases) such as Rab, Rho, and 
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Rac. Small GTPases are significant signaling proteins that regulate various cellular 
processes critical for cell function, including cell morphology, cytoskeletal arrangement, 
trafficking of vesicles, and apoptosis. Prenylation is required for the proper functioning of 
these proteins because the lipophilic prenyl group serves to anchor the proteins in cell 
membranes. Therefore, impaired prenylation of small signaling proteins may cause loss 
of cellular functions that may be followed by apoptotic cell death.144 Moreover, 
previously it has been shown that N-BPs are not metabolized into ATP analogs. 
However, recent studies revealed that N-BPs can also induce formation of a new pro-
apoptotic ATP analog (ApppI, Figure 2.9), as a consequence of the inhibition of FPP 
synthase in the mevalonate pathway. Similar to the ATP analog of non-N-BPs, ApppI can 
induce mitochondria-mediated apoptosis.145  
The differences at the BP side chain produce significant diversity in the potency 
of various bisphosphonates. Among those tested in vitro, zoledronate has the highest 
potency of inhibiting the human farnesyl diphosphate synthase.146  In preclinical models 
of bone resorption, the newer bisphosphonates, such as ibandronate and zoledronate, 
show 10.000- to 100.000-fold higher potency than the older agents such as etidronate and 
clodronate.147 Due to its high potency and efficacy in treatment of bone metastasis, recent 
interest has focused on the use of zoledronate in cancer.  
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Figure 2.9: The mevalonate pathway and proposed mechanism of action for zoledronate. 
Inhibition of farnesyl diphosphate synthase by zoledronate disrupts isoprenoid biosynthesis. 
Insufficient levels of isoprenoid species (farnesyl pyrophosphate, FPP, and geranylgeranyl 
pyrophosphate, GGPP) cause numerous cellular effects, including loss of membrane integrity due 
to deficient cholesterol synthesis, altered cell signaling by blockade of post-translational 
modification of many proteins. In addition, inhibition of FFP synthase leads to accumulation of 
isopentenyl pyrophosphate (IPP). IPP is conjugated to AMP to form a novel ATP analogue, 
ApppI. Adapted from Mitrofan et al., 2010.148  
2.2.3 Pharmacokinetics and biodistrubition of zoledronate 
Since it is a highly charged and water soluble compound, zoledronate robustly 
chelates divalent cations like calcium and thus readily binds to bone.149 In vivo studies 
demonstrated that up to one-half of the administered zoledronate is directly eliminated 
from the body by the kidneys, without biotransformation. The rest is located to bone, 
 
 
INTRODUCTION 
 
 34
where it accumulates. Bone acts as a reservoir for zoledronate and osteoclast mediated 
bone resorption gradually releases the drug during normal bone remodeling. In general, 
zoledronate is a well tolerated drug. The most common adverse effects include skeletal 
pain, anorexia, constipation, fever and nausea.150 Osteonecrosis of the jaw bone is a less 
common side effect that has been reported mainly in patients with cancer who are 
undergoing dental surgery.151 
Animal studies revealed that concentrations of zoledronate in soft tissue were 
about 1–3 orders of magnitude lower than in bone.152 Interestingly, encapsulating 
bisphosphonates into liposomes to target them for macrophage phagocytosis modifies 
their selectivity from osteoclasts to macrophages, and i.v. or i.p. application of liposomes 
containing clodronate can deplete macrophages in the mononuclear phagocytic system 
(MPS), formerly called reticuloendothelial system (RES).153 
 
2.2.4 Anti-tumorigenic properties of zoledronate  
Although zoledronate has originally been developed to inhibit osteoclast mediated 
bone resorption, ongoing studies are now evaluating the anti-cancer effects of this 
compound. In the cancer context, zoledronate is primarily used as adjuvant therapy to 
inhibit local bone destruction by tumors and to prevent or delay metastases to the bone. 
Bone metastases are common in patients with different types of cancers; particularly 
lung, breast and prostate cancers are associated with severe skeletal complications 
including bone pain, pathological fractures, spinal cord compression and hypercalcemia, 
all of which substantially reduce the patient’s quality of life. These skeletal morbidities 
can be treated to a certain extent by exploiting the bone resorption inhibitory properties of 
zoledronate.   
In this regard, a panel of bisphosphonates (including clodronate, pamidronate, 
zoledronate, ibandronate) was clinically tested in advanced breast cancer patients with 
bone metastases. Among the tested BPs, zoledronate exhibited the most substantial and 
consistent clinical benefits related to skeletal morbidity.154,155,156  In another clinical trial 
with advanced renal cancer patients, multiple event analyses have demonstrated that 
zoledronate reduced the risk of developing skeletal related events (SRE) by 61% as 
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compared with placebo.157  Moreover, zoledronate has demonstrated significant clinical 
benefits in patients with metastatic prostate and lung cancer.157,155 In the latter, 
zoledronate was shown to delay the median time to first SRE (236 days with ZA vs. 155 
days with placebo) and to significantly reduce the annual incidence of SREs (1.74 per 
year with ZA vs. 2.71 per year with placebo). Eventually, the drug was found to reduce 
the risk of developing a skeletal event by 31%. Based on these findings, phase III clinical 
trials in cancer patients were completed and zoledronate is registered in the United States 
and Europe for the treatment of bone metastases associated with a wide variety of 
tumors.158  
Numerous recent publications indicated that zoledronate does more than just 
inhibit osteoclast function in the bone. Besides preventing cancer related skeletal 
morbidities, it exhibits diverse anti-tumor activities that can be classified as direct and 
indirect effects. Zoledronate exerts these anti-tumorigenic activities directly on cancer 
cells by modulating their tumorigenic properties and indirectly on stromal cells by 
modulating their tumor-promoting properties.159  
 
2.2.4.1 Direct effects: Modulation of cancer-cell properties 
2.2.4.1.1 Anti-proliferative and pro-apoptotic effect 
Direct effects of zoledronate on cancer cells are mainly tested in in vitro settings. 
One of the major anti-tumor effects of zoledronate is the induction of apoptosis.  Early 
studies have demonstrated an increase in the proportion of cells with altered nuclear 
morphology and fragmented DNA, characteristic of apoptosis, in zoledronate treated 
myeloid cell lines.160 Besides studies exhibiting pro-apoptotic effects, there are various 
reports describing in vitro anti-proliferative effects of zoledronate on different types of 
cancer cells. In a study with the myeloma JJN-3 cell line, the compound was shown to 
arrest the cells in the S-phase of the cell cycle.161 Furthermore, dose and time-dependent 
anti-proliferative and pro-apoptotic effects of zoledronate were also shown in breast 
cancer, prostate cancer, pancreatic cancer, lung cancer and osteosarcoma cells in vitro.162-
164 Several studies attempted to elucidate the mechanisms of the pro-apoptotic effect 
suggested that inhibition of small GTPase prenylation in the mevalonate pathway might 
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be the main mechanism driving zoledronate mediated tumor cell apoptosis.165,166  A study 
with MCF-7 breast cancer cells supported this notion by demonstrating that apoptotic 
activities of zoledronate could be reversed by incubation with geranylgeraniol, a 
downstream metabolite of the mevalonate pathway.162  
Although in vitro data suggest a promising pro-apoptotic effect of the drug on 
tumor cells, the question if this cytotoxic potential translates into equivalent in vivo 
effects in tumor models is currently under investigation. Zoledronate was found to induce 
apoptosis in breast cancer cells at a concentration range between 10-100 μM in vitro.167 A 
critical question is whether these cytotoxic concentrations can be reached in animal tumor 
models and consequently in human patients. As mentioned before, systemic 
concentration of zoledronate is considerably low. Following i.v. administration of a 
standard 4 mg dose of zoledronate, the drug remains in the plasma for 1–2 h before 
locating to bone. The peak plasma levels are estimated to be 1–2 μmol/l that is critically 
lower than the concentration necessary to exert direct anti-tumor effects.168,169 However, 
local drug concentrations in the bone microenvironment may be sufficient to inhibit 
growth of tumor cells in this microenvironment. For this reason in vivo studies have 
mainly focused on the effect of the drug on tumors growing in bone microenvironment 
like multiple myeloma or on bone metastases of various cancers. In this context, in vivo 
data have been published showing that zoledronate may have the potential to reduce the 
tumor load and induce tumor cell apoptosis in corresponding animal models. 170,171  
2.2.4.1.2 Inhibition of adhesion, migration and invasion 
Zoledronate not only influences proliferative and apoptotic properties of cancer 
cells, but also interferes with migratory and invasive properties. Based on results from 
matrigel-based invasion assays, zoledronate appears to inhibit the potential of human 
prostate and breast cancer cells to adhere and invade into the extracellular matrix.172  
These activities could have further implications on the metastatic potential of these 
cancer cells.  In MCF-7 and MDA-MB-231 breast cancer cells, low concentrations of 
zoledronate (100 nM - 10 µM) reduced the number of cells adhering to mineralized and 
non-mineralized matrices by 40-80 %.173 The anti-adhesion effect could not be due to 
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cytotoxicity, because zoledronate is not cytotoxic at doses capable of inhibiting adhesion. 
Since the peak plasma concentration of bisphosphonates in humans is in the micromolar 
range, in vitro anti-adhesive and anti-invasive effects of zoledronate observed at sub-
micromolar concentrations could also be applicable in vivo. In an attempt to uncover the 
molecular mechanisms mediating the anti-invasive activities of zoledronate, Teronen et 
al. demonstrated that the matrix metalloproteinases MMP-3, -12, -13, and -20 are 
inhibited by zoledronate in osteosarcoma, melanoma and fibrosarcoma cell lines in 
vitro.174 Another study by Boissier and colleagues suggested that zoledronate did not 
interfere with the production of MMPs by tumor cells, but  inhibited their proteolytic 
activity through zinc chelation.175 
2.2.4.2 Indirect effects: Modulation of tumor microenvironment 
Apparently, zoledronate can directly affect certain properties of tumor cells, albeit 
mostly within the bone microenvironment. Since, as mentioned before, serum 
concentrations of zoledronate are far below the required threshold to directly inhibit 
tumor cell proliferation or induce apoptosis, it is not clear whether its anti-tumor 
activities could reach beyond the bone. Moreover, physicochemical properties like 
negative charges of zoledronate prevent it from moving across cell membranes and 
minimize cellular uptake. In this respect, potential anti-tumor effects of zoledronate in 
non-skeletal tumors cannot be solely attributed to direct killing of cancer cells.  A few 
recent studies demonstrated the anti-tumor activities of zoledronate on soft-tissue 
tumors.176-178 These findings suggest that clinically observed effects of zoledronate 
treatment may also be explained by indirect mechanisms regulating the modulation of the 
tumor microenvironment.  
2.2.4.2.1 Inhibition of angiogenesis  
Zoledronate was shown to impair tumor growth indirectly by inhibiting 
angiogenesis. Anti-angiogenic properties of the compound were evaluated in a number of 
studies. In vitro assays showed that treatment of human umbilical vein endothelial cells 
with low concentrations of zoledronate (1-30 µM) inhibited cell proliferation,  whereas 
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higher concentrations (100 µM) induced apoptosis.179 In another study, zoledronate was 
also shown to inhibit differentiation and the ability to form capillary-like tubes of 
endothelial progenitor cells even at low concentrations (1 µM).180  
Results of several in vivo studies demonstrated that zoledronate inhibits 
angiogenesis in experimental angiogenesis models and lowers the levels of circulating 
pro-angiogenic factors in tumor bearing mice and cancer patients.181 The first study 
indicating an inhibitory effect of zoledronate on angiogenesis occurring in non-
mineralized tissue was performed by Wood et al.179 In this study, systemically 
administrated zoledronate inhibited angiogenesis induced by subcutaneous implants 
impregnated with bFGF and VEGF in a mouse model. In a transgenic mouse model of 
cervical cancer, zoledronate therapy (100 µg/kg daily, sc) increased epithelial and 
endothelial cell apoptosis in tumors without affecting hyperproliferation, indicating that 
zoledronate is not anti-mitotic at that concentration.176 Further analyses in the same study 
suggested a cellular and molecular mechanism involving inhibition of MMP-9 expression 
and activation of tumor infiltrating macrophages, thereby reducing association of VEGF 
with its receptor on endothelial cells.176 In a clinical study, cancer patients with advanced 
solid cancer and bone metastases were treated with a standard single administration of 4 
mg zoledronate. In treated patients, a statistically significant decrease in the serum levels 
of the circulating angiogenic factors VEGF and PDGF was detected. Zoledronate clearly 
induced a long lasting effect because even 21 days after the first infusion of zoledronate 
VEGF serum levels remained significantly below basal values.181 These studies suggest a 
variety of mechanisms that may elucidate the anti-angiogenic activities of zoledronate, 
however the precise molecular and cellular mechanisms responsible for these effects in 
the in vivo studies are still unclear.  
2.2.4.2.2 Immunomodulatory effect  
In addition to anti-angiogenic effects, zoledronate is thought to modulate the 
immune system to target and eliminate cancer cells. The immune modulatory activities of 
zoledronate include stimulation of proliferation and activation of the Vγ9Vδ2 subset of 
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γδT cells. T cells expressing the Vγ9Vδ2 T cell receptor play a significant role in immune 
system surveillance and defense.182 In fact, these cells have potent ability to recognize 
and kill tumor cells in an MHC-independent manner, suggesting their potential utility in 
elimination of cancer cells with poor antigen presentation capacity.183 γδT cells are 
known to be stimulated by IPP which is an intermediate metabolite of FPP synthesis in 
the mevalonate pathway. (see Figure 2.9)  Internalization of zoledronate by cancer cells 
leads to inhibition of FPP synthase, resulting in intracellular accumulation of IPP.184 In 
vitro studies with breast cancer and myeloma cells showed that zoledronate treated cells 
accumulated phosphorylated mevalonate metabolites (IPP) and then presented those IPP 
ligands to TCR-γδ cells by an as yet unidentified mechanism.185,186 Presentation of IPP to 
γδT cells was shown to stimulate proliferation and subsequent activation of those cells. 
Consequently, cell lines pre-treated with 5 µM zoledronate showed a marked increase in 
sensitivity to lysis by activated γδT cells.187 Several pre-clinical studies have 
demonstrated that Vγ9Vδ2 T cells expanded in vitro sustain their anti-cancer activity in 
vivo upon adoptive transfer into nude mice transplanted with various human cancer cells 
along with zoledronate treatment.188-190 Furthermore, clinical studies with cancer patients 
also support the results of preclinical studies by demonstrating in vivo expansion and 
activation of Vγ9Vδ2 T cells to a subset of IFN-γ producing effector T cells in patients 
treated with zoledronate, either alone or in combination with low-dose IL-2.191 Besides 
cancer cells, monocytes treated with zoledronate were also shown to accumulate IPPs and 
stimulate proliferation and cytotoxic activation of human Vγ9Vδ2 T cells.  Notably, 
activation of γδT cells requires cell-to-cell contact with zoledronate treated tumor cells or 
monocytes.186 
Activated γδ T cells might exert an anti-cancer activity by various mechanisms. 
As a response to zoledronate mediated activation, γδ T cells secrete TNF-α and IFN-γ 
which stimulate anti-tumor activity of APCs (NK cells, dendritic cells , macrophages) 
and αβ T cells.192 Another mechanism through which zoledronate exerts γδT cell 
mediated cytotoxicity includes secretion of perforin and granzymes, causing direct tumor 
cell cytotoxicity.193  Vγ9Vδ2 lymphocytes also express the activating NK cell receptor 
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NKG2D which is important for cancer cell recognition by zoledronate activated γδT 
cells. Through this receptor γδT cells recognize the cancer cells that express the stress 
inducible MICA/MICB proteins.194  
Apparently, zoledronate could have a noticeable effect on the γδT cell mediated 
immune response which might contribute to their in vivo anti-tumor activity. However, 
those findings do not help to explain the mechanism of anti-tumor activity of zoledronate 
in mouse tumor models because the Vγ9Vδ2 T cell subset exists only in primates. 
Currently it is unclear if an analogous T cell subset exists in rodents.   
Although, all those indirect anti-tumor effects were demonstrated in vitro, it is 
difficult to assess in vivo if they are associated with osteoclast inhibitory effects of 
zoledronate. 
2.2.4.2.3 Inhibition of the release of bone derived growth factors  
Considering the high concentrations of zoledronate reached in the bone-
microenvironment and its inhibitory effect on osteoclast activity, it is conceivable that 
anti-tumor effects of zoledronate are likely to be mediated indirectly through the 
inhibition of bone resorption. Reduced bone resorption results in decreased release of 
bone-derived growth factors that are necessary for the survival of metastatic tumor cells, 
thereby creating a less favorable microenvironment for the invasion and survival of 
metastatic tumor cells.  
 Devastating bone destructions are common in patients with various advanced 
cancers like breast, prostate, kidney and lung cancer. Those tumors often have destructive 
localized or systemic effects on the skeleton. Localized effects are mediated by bone-
residing metastatic deposits and lead to bone destruction, bone formation or both. On the 
other side, systemic skeletal destructions do not require presence of bone-residing 
tumors. These effects are mediated via primary tumor released circulating cytokines and 
other factors.195 To stimulate systemic and/or local bone destruction, tumor cells secrete 
multiple factors such as parathyroid hormone-related peptide (PTHrP), IL-11, IL-6, TNF, 
RANKL and TGF-α which potently induce osteoclastic activity. Early studies revealed 
that the majority of patients with solid tumors have increased plasma PTHrP 
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concentrations. In parallel, women with PTHrP-positive primary breast tumors are more 
likely to develop bone metastases.196 PTHrP and other tumor-released factors induce 
osteoclastic bone degradation that leads to subsequent release of bone-bound growth 
factors. Bone is a rich reservoir of growth regulatory substances (e.g. transforming 
growth factors (TGF-β), insulin-like growth factors (IGFs), fibroblast growth factors 
(FGF), bone morphogenic proteins (BMP), platelet-derived growth factors (PDGFs) and 
others) which are released during osteoclastic bone resorption.197 Those growth factors, 
in turn, stimulate tumor cell proliferation and production of more osteolytic factors, 
which further promote osteoclastic bone resorption. Thus, reciprocal interactions between 
cancer cells and the microenvironment create a self-perpetuating circle of bone 
destruction and tumor growth that is called “vicious cycle of bone” (Figure 2.10).198  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Cancer cells secrete PTHrP as the primary stimulator of osteoclastogenesis as 
well as other factors e.g. IL-6, prostaglandin E2 (PGE2), TNF and M-CSF increasing 
formation of osteoclasts. During bone resorption, osteoclasts release TGF-β, insulin-like growth 
factors (IGFs), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and bone 
morphogenetic proteins (BMPs), which further induce the production of PTHrP by tumor cells, as 
well as growth factors that support tumor growth. This represents the vicious circle that promotes 
bone destruction and tumor growth. Bisphosphonates break this vicious cycle by inhibiting 
osteoclast activity in bone. Adapted from Mundy and Yoneda, 1998.199 
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 By inhibiting osteoclastic activity, zoledronate was shown to reduce the local 
release of growth factors from bone and break this self-perpetuating stimulatory 
mechanism, resulting in a less hospitable environment for tumor growth.200 Among these 
growth factors, TGF-β is known as the most abundant cytokine in bone and considered as 
the main bone-derived factor responsible for driving this vicious cycle of bone 
metastasis. All three isoforms of TGF-β are present in bone matrix in their latent form. 
During osteoclastic resorption, the pH is decreased and an acidic microenvironment 
activates TGF-β in bone.201 Activated TGF-β is released from mineralized bone matrix 
and in turn induces production of tumor-derived osteolytic factors.202,203 Subsequently, 
tumor derived bone resorption might result in higher levels of TGF-β in the peripheral 
blood. In cancer patients, higher serum concentrations of TGF-β were detected at later 
stages of cancer. Elevated serum levels of TGF-β were shown to correlate with enhanced 
bone metastasis and poor clinical outcome in the late stage of colorectal carcinoma, lung 
cancer and melanoma.204-206 Yin J. et al. showed that blockade of TGF-β signaling in 
breast cancer cells resulted in decreased osteolysis, less tumor burden in bone and 
enhanced survival in mice bearing tumors.207 In a study with breast cancer bearing mice, 
Kang et al. demonstrated that mice treated with BPs (zoledronate or pamidronate) 
showed less destruction of bone matrix and accordingly a reduced activation of the TGF-
β signaling pathway in cancer cells of bone metastases. The authors proposed that these 
effects might be associated with lowered bioavailability of active TGF-β in 
bisphosphonate treated mice. The study further revealed that although it does not affect 
TGF-β signaling in cancer cells in vitro, zoledronate can hinder TGF-β signaling in vivo 
by inhibiting osteoclast activity and consequently preventing release of TGF-β from bone 
matrix.200 These data suggest that modulation of bone derived factors like TGF-β might 
also be a possible mechanism responsible for the anti-tumor activity of zoledronate. 
However, whether zoledronate mediated inhibition of bone derived factors could also 
exert such an indirect anti-tumor effect in peripheral tissues remains unclear. 
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Figure 2.11: In vitro and in vivo anti-tumor effects of zoledronate. Zoledronic acid was shown 
to inhibit angiogenesis, cell invasion, cell adhesion, bone metastasis, bone resorption, and cell 
proliferation as well as activating Vγ9Vδ2 T cells. Lipton et al, 2011.208 
 
All together, pre-clinical studies suggest diverse anti-cancer effects of zoledronate 
in different tumor models (Figure 2.11). Furthermore, clinical studies showed that 
zoledronate prolongs disease-free survival in cancer patients.209 However, an exact 
mechanism by which zoledronate prevents disease progression is still a topic of 
investigation. Certain other issues still remain uncovered. Does the clinically relevant 
dose of zoledronate prevent tumor progression in soft tissue tumors and if so, what are 
the mechanisms underlying this anti-tumor function?  Identification of new cellular 
targets and further elucidation of the cellular and molecular mechanisms by which 
zoledronate mediates anti-tumor effects would be useful in the design of new therapeutic 
strategies to modulate and potentiate the anti-tumor effects of this compound. 
 
 
RESULTS 
 
 44
3. RESULTS  
3.1 Zoledronate induces apoptosis and delays tumor growth in syngeneic mouse 
tumor models 
Due to its high affinity for bone matrix, zoledronate has been extensively studied 
for its activity against tumors located in bone and against bone metastases. Recently, a 
few studies reported growth inhibitory effect of zoledronate on soft tissue tumors. 
Although the target cells and exact mechanism of action are still unknown, recent studies 
suggest a possible involvement of myeloid cells in the antitumor activities of the drug. 
On the basis of these recent findings, we aimed to evaluate the potential immuno-
modulatory and anti-tumorigenic properties of zoledronate in syngeneic mouse tumor 
models. As an initial step to this end, we first evaluated the anti-tumor effects of 
zoledronate in immunocompetent C57BL/6 mice that were inoculated subcutaneously 
with Lewis Lung Carcinoma (LLC) cells, and then treated repeatedly with either 
zoledronate or vehicle control during the course of tumor growth.  
To evaluate the therapeutic potential as well as the antitumor activity of 
zoledronate, the treatment was started only when tumors had reached a size of about 50 
mm3, which was approximately 7 days after tumor cell implantation (Figure 3.1A). 
Further to this end, zoledronate was applied at clinically relevant doses (i.e., 3 
μg/mouse).210 On average, each mouse received six injections of the drug (a cumulative 
dose that did not exceed 18 μg throughout the tumor growth analysis) and the animals 
were monitored for tumor growth and body weight. Mice tolerated the dose well and 
showed no apparent significant adverse effects. After an initial lag phase, LLC tumors 
showed rapid growth. However, in comparison to vehicle treated mice, those treated with 
zoledronate exhibited a significant delay in tumor growth as shown in Figure 3.1B. At the 
end of the treatment period, the average size of LLC tumors in zoledronate-treated mice 
was 60% smaller than those in the control group. The tumor growth reduction effect of 
zoledronate was an early event, already apparent after the first three courses of drug 
application.                                                                     
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A.  
 
 
 
B. 
 
 
 
 
 
Figure 3.1: Zoledronate administration impairs subcutaneous LLC tumor growth. (A) 
Scheme of tumor inoculation and zoledronate treatment protocol. C57/BL6 female mice were 
subcutaneously inoculated with LLC cells (5x105) suspended in 50 µl HBSS at day 0. When 
LLC tumors reached a volume of ~50 mm3 (around day 7), mice were randomized to 
receive i.p injections of zoledronate (3µg in 100µl HBSS) or vehicle (100 µl HBSS) as a control. 
Treatments were repeated every other day until sacrifice. (B) Tumor size was measured once 
every second or third day and tumor volume was calculated as described in Material and 
Methods. Tumor growth expressed as mean tumor volumes ±SEM for each treatment group was 
significantly delayed in zoledronate treated animals. *P<0.05. Data shown is representative of 
five independent experiments with similar results.  
To further evaluate whether other tumor types could respond to zoledronate in a 
similar way, two different syngeneic tumor models, namely melanoma (B16) and colon 
adenocarcinoma (MC38), were also tested. As shown in Figure 3.2A, significant 
inhibition of MC38 tumor growth was observed in treated animals, though the effect was 
less pronounced than for LLC tumors. However, treatment of B16 melanoma-bearing 
mice with zoledronate resulted in a moderate but non-significant reduction of tumor 
growth with respect to the control group. (Figure 3.2B)  
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A.                                                                            B. 
 
 
 
 
 
 
 
 
 
Figure 3.2: Zoledronate significantly restricts tumor growth in the syngeneic mouse tumor 
models MC38 colon carcinoma but not in B16 melanoma. C57/BL6 female mice were 
subcutaneously inoculated with MC38 (A) or B16 (B) cells (3x105) suspended in 50 µl HBSS at 
day 0. When tumors reached a volume of ~50 mm3, mice (n=7 per group) were treated with 
zoledronate (3 μg/mouse, i.p.) or HBSS (control) according to the schedule shown in Figure 
3.1A. Treatment was started on day 8 and continued every 2nd day until sacrifice. Results are 
presented as mean tumor growth ±SEM. *P<0.05. Data are representative of three independent 
experiments. 
 
To investigate the mechanism underlying the growth inhibitory activity of 
zoledronate, the potential anti-proliferative and pro-apoptotic properties of the drug were 
examined in the LLC tumor model. Sections of tumor samples were analyzed for 
apoptotic and mitotic incidences. To this end, immunostaining for the mitosis-specific 
antibody anti-phosphohistone H3 was performed in order to detect proliferating cells. As 
a marker for apoptosis, the activated form of caspase-3, an effector of the apoptotic 
program, was monitored by IHC. Microscopic analysis revealed that zoledronate 
treatment had no impact on tumor cell proliferation in vivo (Figure 3.3A). However, a 
marked increase was observed in the number of apoptotic cells in zoledronate treated 
tumors as compared with vehicle treated tumors (Figure 3.3B). As the systemic 
concentrations of zoledronate that are achievable in vivo do not have a cytotoxic effect on 
cancer cells in vitro 211,212, stromal rather than cancer cell-autonomous mechanisms might 
account for increased apoptosis in vivo.  We therefore sought to clarify whether the 
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zoledronate-induced tumor apoptosis and growth reduction were caused by 
microenvironmental stress such as the limitation of nutrients/growth factors/oxygen due 
to impaired angiogenesis or by cytotoxic immune response. 
Tumor-associated angiogenesis which is mediated, in part, by tumor infiltrating 
myeloid cells plays a crucial role in tumor growth and metastasis. Because 
bisphosphonates have been reported to have anti-angiogenic properties and thereby 
interfere with tumor growth in several tumor models, we investigated whether the 
observed growth reduction by zoledronate was associated with inhibition of angiogenesis. 
IHC analysis of LLC and MC38 tumor tissues was performed in each treatment group to 
investigate the potential effect of zoledronate on the angiogenic status of the tumors. 
Anti-CD31 antibody was applied to detect tumor blood vessels. No significant 
differences were found in the mean vascular density (MVD) of zoledronate-treated LLC 
or MC38 tumors versus their untreated controls (Figure 3.3C and suppl. Figure 1). This 
finding suggests that zoledronate impairs tumor growth through mechanisms that are 
independent of angiogenesis regulation. 
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A.  
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C.     
 
 
 
 
Figure 3.3. Effect of zoledronate treatment on proliferative, apoptotic and angiogenic status 
of tumors. LLC tumors excised from zoledronate treated and untreated animals were embedded 
in paraffin, sectioned, and subjected to IHC. Proliferative and apoptotic response of tumors to 
zoledronate treatment were examined. (A) Representative images of pHH3 IHC (left panel). 
Quantification of pHH3 staining, revealing no changes in the number of proliferating tumor cells 
in treated and untreated tumors (right panel). (B) Representative images of caspase-3 IHC (left 
panel).Quantification of staining for cleaved caspase-3 revealed increased numbers of apoptotic 
cells in treated tumors compared to the controls (right panel). Scale bar, 200 μm. Right panels 
depict mean numbers of pHH3+ or caspase-3+ cells per field ±SEM (×100 magnification). The 
number of apoptotic or proliferative cells in a given field (0.8x0.6 mm) was counted for 
quantitative analysis. In this context, 20 fields per section were counted.  Tumors from five 
different animals were examined for each experimental group of mice. (C) Representative images 
of CD31 IHC (left panel).  Right panels depict mean numbers of vessels per field ±SEM (×100 
magnification). Microvessels were counted in five randomly selected fields of tumors from four 
mice of each group. The differences between controls and treated groups were analyzed by 
unpaired two-tailed Student's t test. 
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3.2 Zoledronate induces enhanced infiltration of myeloid cells into tumors 
As discussed in section 2.1.2, tumor growth is largely supported by tumor- 
infiltrating myeloid cells, in particular macrophages and neutrophils, and therefore 
depletion of these cells is often associated with tumor regression. Due to their high 
endocytic activity, myeloid cells are in a privileged position to internalize zoledronate. 
Based on these facts, we predicted an influence of zoledronate on myeloid cells and next 
set out to investigate whether zoledronate could mediate growth inhibitory effects 
through the depletion of myeloid cells. Therefore, the frequency of myeloid cells in 
tumors of treated and untreated animals was analyzed. A GFP reporter mouse model 
named MacGreen that expresses GFP under the control of the CSF1-receptor promoter in 
cells of the myeloid lineage was utilized for the thorough detection and isolation of 
myeloid cells.213 It is worth noting that as these MacGreen mice express the reporter 
molecule GFP in cells of the monocyte/macrophage lineage213 and granulocytes214, most 
GFP expressing cells also express CD11b  antigen.  
At the end of the treatment period, single cell suspensions prepared from tumors 
of each individual treated and untreated animals were analyzed by flow cytometry to 
assess the relative abundance of GFP+ myeloid cells in the tumor mass. Unexpectedly, no 
decrease was observed in the frequency of myeloid cells in treated tumors, suggesting 
that zoledronate does not show cytotoxicity against myeloid cells at the concentrations 
used in this study. In contrast, the treated tumors surprisingly exhibited higher 
percentages of GFP+ myeloid cells than the untreated tumors (Figure 3.4A). Consistent 
with the flow cytometric data, IHC analyses of tumor sections also confirmed the higher 
incidence of myeloid cells in zoledronate-treated LLC tumors (Figure 3.4C). A similar 
pattern was also observed in the MC38 tumor model, but the effect was less pronounced. 
However, B16 tumors did not exhibit significant changes in the frequency of myeloid 
cells upon treatment (Figure 3.4A-B). Notably, there was a marked correlation between 
myeloid cell infiltration in these tumors and the outcome of zoledronate treatment. B16 
tumors, which do not exhibit significant growth reduction in response to the drug showed 
only modest infiltration of myeloid cells (approximately 1.5 % of total cells) when 
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compared with LLC tumors (approximately 10 % of total cells). In the same way, the 
modest increase in the percentages of myeloid cells in MC38 tumors correlates with the 
comparatively limited growth inhibitory effect of the drug in this model (Figure 3.4 A-B). 
The finding of an increased frequency of myeloid cells in the treated tumors prompted us 
to analyze in turn the frequency of myeloid cells in the bone marrow, blood and spleen 
harvested from control and treated tumor-bearing mice. After intake, zoledronate is 
deposited mainly in the bones and as a consequence of osteoclast resorption, is released 
into the bone marrow wherein it might stimulate the proliferation of myeloid progenitors 
or their mobilization to peripheral blood. To examine this possibility, bone marrow cells 
of zoledronate-treated LLC tumor-bearing mice were analyzed for the enrichment of 
myeloid progenitors. However, evaluation of myeloid cells of treated versus untreated 
mice revealed that zoledronate treatment did not significantly affect the frequency of 
myeloid cells in the bone marrow (41.6 ± 4.59 % in control versus 44.13 ± 1.61 % in 
zoledronate treated mice, Figure 3.4G). A small but significant difference was found in 
the blood, with the frequency of GFP+ myeloid cells being slightly higher in treated 
compared to untreated mice (Figure 3.4F). In the spleen and peritoneum however, 
percentages of myeloid cells were notably increased in zoledronate-treated mice (Figure 
3.4D-E). These results suggest an altered recruitment of these cells or a change in their 
endogenous migratory capabilities of these cells in zoledronate treated animals.  
The counterintuitive correlation of enhanced myeloid cell infiltration with the 
delayed tumor growth observed in zoledronate-treated mice suggests a causative 
relationship between myeloid cells and the anti-tumor effect of the drug. Therefore, to 
investigate the possible role of myeloid cells in zoledronate-induced growth delay, these 
cells were examined in relation to activation status.   
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3.3 Myeloid cells from zoledronate-treated mice are skewed towards an antitumor 
phenotype 
Although intra-tumoral accumulation of myeloid cells has been widely reported  to 
be associated with enhanced tumor growth,100,215 in our experiments increased 
accumulation of myeloid cells in zoledronate-treated tumors was found to be correlated 
with delayed tumor growth. This suggests that zoledronate may induce changes in the 
activation status of myeloid cells which transforms them into anti-tumorigenic types. As 
discussed in the previous section, anti-tumorigenic activation of myeloid cells is associated 
with changes in the expression patterns of various inflammatory mediators, and also 
manifested through differential expression of certain (e.g. M1 or M2 related) cell surface 
antigens. To assess whether zoledronate induces such an anti-tumorigenic phenotype in 
myeloid cells, GFP+ cells isolated from both LLC and MC38 tumors of zoledronate-treated 
and untreated mice (Figure 3.5A) were subjected to real-time RT-PCR for the analysis of 
differential expression of relevant M1 and M2 activation state markers, which represent 
anti/pro-tumorigenic phenotypes respectively. Not only the tumor infiltrating but also the 
peritoneal myeloid cells were analyzed for their differential activation status. This was 
because, peritoneal myeloid cells of tumor-bearing mice are known to exhibit a pro-
tumorigenic phenotype which is characterized by the increased expression of 
immunosuppressive cytokines as well as reduced expression of immunogenic factors.114  
 
 
Figure 3.4: Zoledronate causes changes in the extent of myeloid cell infiltration in tumor-
bearing mice The s.c. LLC, B16 and MC38 tumor-bearing MacGreen mice were either treated with 
zoledronate or vehicle (n=6-8/group; i.p.) as described in Materials and Methods. Mice were 
sacrificed 24h after the last treatment, and tumors were harvested and processed. Percentages of 
GFP+ cells in LLC, B16 and MC38 tumor cell suspensions were analyzed by flow cytometry (A) 
shows a representative tracing of GFP+ cells in tumors of each cell lines. The numbers in each 
square represent the percentage of GFP+ cells in the tumor mass. (B) summarizes percentages of 
GFP+ cells in both treated and untreated groups. (C) IHC of LLC tumors, confirming enhanced 
infiltration of GFP+ myeloid cells (green) into tumors of treated mice. Sections are representative of 
multiple samples from more than four experiments. (D-G) summarizes percentages of GFP+ cells in 
blood, spleen and peritoneal lavage fluid of mice bearing tumors of each cell lines (D-F) and in the 
bone marrow of LLC bearing mice (G). Data are representative of three independent experiments 
and show mean ± SEM of 6-8 mice. Statistical significance was assessed by two-sided Student’s t-
test.  
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As shown in Figure 3.5B, quantitative real-time PCR data revealed a marked 
decrease in expression of the immunosuppressive cytokines IL-10 and arginase-1 in the 
GFP+ myeloid cells of zoledronate-treated tumors. On the other hand, a simultaneous 
increase in the expression of the immunostimulatory factors IL-12, IFN-γ and iNOS 
suggests an anti-tumorigenic reprogramming of these cells. Furthermore, the acquisition of 
a M1-like phenotype by myeloid cells from treated tumors was reflected by their increased 
expression of MHC  class II molecules as well as by a decreased expression of the 
scavenger receptor CD163, which has recently been proposed as a marker to characterize 
the pro-tumorigenic activated M2-type macrophages.216,217 IHC analysis of tumor tissue 
sections further demonstrated that even though the total number of myeloid cells was 
increased, the number of CD163 positive myeloid cells was significantly decreased in 
treated tumors (suppl. Fig.3.2). Peritoneal myeloid cells from treated mice also exhibited a 
comparable polarization from M2 to M1 phenotype (Figure 3.5C).  Evidently, zoledronate 
treatment skewed the myeloid cells from an M2-like immunosuppressive phenotype to an 
M1-like immunostimulatory phenotype.  
To further evaluate the immunostimulatory capacity of myeloid cells from treated 
tumors, we tested their effect on CD8+ T cell proliferation and activation in vitro. GFP+ 
myeloid cells isolated from tumors of treated or untreated animals were co-cultured with 
fluorescent dye CFSE labeled CD8+ T cells isolated from spleens of non-tumor bearing 
naïve animals. As expected and as shown in Fig. 3.6A-B, myeloid cells from zoledronate-
treated tumors showed enhanced capacity to stimulate allogeneic CD8+ T cell proliferation 
and IFN-γ production.  
It is highly probable that these M1-activated immunostimulatory myeloid cells play 
an important role in the observed effect of the drug on tumor growth.  
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Figure 3.5 Myeloid cells of zoledronate treated mice exhibit a more immunostimulatory gene 
expression profile. LLC and MC38 tumors were removed from treated or untreated mice at the end 
of the treatment period. Single cell suspensions were prepared and myeloid cells isolated based on 
FACS sorting for GFP+ cells. (A) Single cell sorting of GFP+ cells from tumors of LLC bearing 
mice. A representative flow cytometric analysis of GFP+ cells before and after sorting is shown. (B-
C) RT-PCR analysis revealing that myeloid cells sorted from tumors (B) and the peritoneal cavity 
(C) of zoledronate treated LLC and MC38 tumor bearing mice express reduced levels of IL-10, 
arginase and CD163 and increased levels of IL-12, IFN-γ, MHC-II and iNOS. Results are given as 
fold increase in mRNA expression relative to that in myeloid cells from untreated mice. Data were 
normalized to β-actin gene expression and are representative of 3 independent experiments. Graphs 
represent the mean (±SEM) of four individual tumor samples. The significance was determined by 
one-sample t test (*p<0.05, **p<0.01, ***p<0.001) 
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A.  
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Figure 3.6. Myeloid cells from tumors of zoledronate treated mice increase the proliferation 
and IFN-γ production of CD8+ T cells in vitro. GFP+ cells isolated from tumors of treated and 
untreated animals were co-cultured with CFSE labeled CD8+ T cells sorted from spleens of naïve 
mice as described in Material and Methods. A total of 3x104 GFP+ cells were cultured with CFSE-
labeled CD8+ T cells (1×105 cells, ratio 1:3) and incubated at 37°C in 5% CO2 for 72 h.  In vitro 
CFSE proliferation (A) and IFN-γ production (B) of CD8+ T cells were measured by flow 
cytometry. Left panels show a representative flow cytometry tracing of CD8+ T cells co-cultured 
with myeloid cells from treated or untreated tumors. Right panels show mean percentages of 
proliferating or IFN-γ producing CD8+ T cells out of total CD8+ T cells co-cultured with myeloid 
cells. Data are representative of 2 independent experiments (n = 3 mice per group). Statistical 
significance was assessed by two-sided Student’s t-test. 
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3.4 Neutrophils are the augmented subset of myeloid cells in zoledronate treated 
tumors 
Tumors recruit a wide variety of myeloid cell types distinguishable by their 
functions as well as by their expressions of specific cell surface markers and as discussed 
earlier, different compositions of myeloid subsets in the tumor microenvironment can give 
rise to different therapeutic responses by the tumor.218 With this perception in mind we next 
set out to characterize the cellular composition of the infiltrating myeloid cells in order to 
identify the subpopulation(s) differentially accumulating in tumors of zoledronate-treated 
animals. To this end, single cell suspensions of tumors were analyzed for various myeloid 
cell surface markers that define macrophages (F4/80), monocytes (CD11b), neutrophils 
(Ly6G) and dendritic cells (CD11c). As shown in Figure 3.7, no significant changes in the 
frequency of infiltrating macrophage or dendritic cell populations were observed in 
response to the treatment. However, a slight increase was detected in the percentages of 
infiltrating CD11b+ cells.  Both neutrophils and monocytes/macrophages express CD11b. 
To differentiate monocytes/macrophages from neutrophils, the anti-Ly6G antibody (clone 
1A8) which is specific for neutrophils was used.219 Zoledronate treatment led to a 
significant increase in the percentage of intratumoral Ly6G+ neutrophils in LLC tumors 
(3.41 ± 0.33 % for zoledronate-treated versus 1.75 ± 0.26 % for controls). B16 and MC38 
tumors exhibited only a slight, and non-significant, increase in neutrophil content upon 
treatment (Figure 3.7).  
Evaluation of myeloid cell subsets in spleen and blood of mice treated with 
zoledronate showed a similar pattern of a slight increase in the percentage of 
Ly6G+CD11b+ neutrophils in comparison to untreated mice. However, as predicted, 
analysis of bone marrow showed no change in the abundance of any of the monocytic or 
neutrophil cell populations (suppl. Fig. 3). Increased frequency of neutrophils in treated 
tumors, spleens and blood, but not in bone marrow suggest that zoledronate does not induce 
the enhanced expansion or differentiation of neutrophils in the bone marrow but that 
alternatively it induces increased chemoattraction and consequent release of neutrophils 
from bone marrow, thereby resulting in their increased infiltration into tumors.    
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Figure 3.7: Enhanced numbers of Ly6G+ neutrophils in tumors of zoledronate treated mice. 
Single cell suspensions were prepared from tumors of treated and untreated animals and infiltrating 
myeloid cell populations were analyzed by flow cytometry. Patterns of tumor-infiltrating myeloid 
cells in mice, presented as the frequency of infiltrating CD11b+, Ly6G +, F4/80+, CD11c+ cells, 
gated on GFP+ cells, in zoledronate treated LLC tumors relative to untreated LLC tumors are 
shown. (A) Representative plots of cells derived from LLC tumors of individual mice are shown. 
(B) Relative percentages of monocytes, neutrophils, macrophages, and dendritic cells. Numbers 
represent the percentage of the relevant population in the tumor mass. Data are representative of 2-3 
independent experiments (n = 6-8 mice per group). Statistical significance was assessed by two-
sided Student’s t-test.  
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3.5 Zoledronate enhances expression of neutrophil chemoattractants in tumors  
Neutrophil recruitment into tumors is tightly regulated by chemokines that are 
produced by both stromal and tumor cells. The increased neutrophil infiltration into tumors 
of zoledronate-treated animals suggested a possible increase in the production of neutrophil 
chemoattractants by these tumors compared to control tumors. This was examined by 
analyzing the mRNA expression levels of several chemokines (i.e. CXCL1/KC, 
CXCL2/MIP-2α, CCL3/MIP-1α, and CXCL5/LIX) that play an important role in the 
recruitment and chemoattraction of neutrophils. As shown in Figure 3.8A, treated tumors 
exhibited a 2.8- and 4.4-fold increase in the expression levels of CXCL2 and CXCL5, 
respectively. CXCL5 is frequently described as a bona fide chemokine for neutrophil 
migration220 and these results are strengthening our hypothesis that the increase in 
neutrophil counts in tumors following zoledronate treatment is at least partly due to their 
increased chemotactic migration. No difference was observed in the expression levels of 
the two other tested chemoattractants, CXCL1 and CCL3, in zoledronate treated tumors.  
Tumors are highly heterogeneous in their cellular composition and these 
chemokines are known to be produced by distinct cells types in this microenvironment. 
Therefore we next sought to nail down the cellular sources of these chemokines in treated 
tumors. Initially tumor-infiltrating myeloid cells were tested as a potential source of 
neutrophil chemoattractants. Myeloid cells isolated from treated and untreated tumors were 
analyzed for differential expression of the chemoattractants shown in Figure 3.8B. Myeloid 
cells from zoledronate-treated tumors exhibited a 2-fold increase in CXCL5 expression but 
did not show any significant changes in the expression of the other selected chemokines. To 
investigate whether cancer cells themselves also contribute to elevated expression of 
neutrophil chemoattractants in treated tumors, we made use of LLC cell line in vitro.  
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A.                                                                                     
 
 
 
 
 
 
 
 
 
 
 
B.                                                                                  C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Induction of neutrophil attracting chemokines in tumors following zoledronate 
treatment. (A) LLC tumors (n =5 per group) from treated and untreated mice were harvested and 
homogenized. RNA was isolated and synthesized cDNA was analyzed using real-time PCR for the 
expression of relevant neutrophil chemoattractants. Fold changes and p-values are shown, relative 
to untreated control. (B) Myeloid cells were isolated from treated and untreated tumors (n=4 per 
group) and assayed for the differential expression of neutrophil chemoattractants. Experiments were 
done twice with at least five animals per group. (C) LLC cells (5x105 cells/well into a 6 well culture 
plate) were placed in culture either without or with 2 µM zoledronate for 4 hours. cDNA was 
assayed for chemoattractant expression. The results shown represent three separate experiments. 
Statistical significance was determined by one-sample t-test. 
 
Expression levels were examined in LLC cells cultured under zoledronate 
supplemented versus normal culture conditions. As shown in Figure 3.8C, zoledronate led 
to a significant increase in the expression of CXCL1, CCL3 and CXCL5 mRNA. 
Expression of CXCL2 mRNA was undetectable probably due to low intrinsic expression. 
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Although CXCL2 was found to be upregulated in treated tumor tissue, neither LLC nor 
myeloid cells exhibited increased levels of CXCL2 mRNA. It is possible that other stromal 
compartments such as epithelial cells or fibroblasts, may be responsible for the observed 
increase in CXCL2 expression in treated tumor tissue. 
These findings suggest that zoledronate could augment the intratumoral recruitment 
of neutrophils by inducing secretion of chemoattractants, which are at least partially 
derived from both the myeloid and cancer cell compartments of tumors.  
 
3.6 Zoledronate treatment induces an immunostimulatory profile in intratumoral 
neutrophils 
 While tumor associated neutrophils are known to support tumor growth, the inverse 
correlation observed between neutrophil abundance and tumor growth observed in 
zoledronate-treated mice suggests that this treatment could induce neutrophils to adopt 
unique phenotypic and functional properties. Given that as was shown in section 3.3 
myeloid cells in general are skewed toward a pro-inflammatory and anti-tumorigenic 
phenotype by zoledronate, two major subsets of myeloid cells, namely CD11b+Ly6G+ 
neutrophils and CD11b+Ly6G- monocytes/ macrophages were analyzed for changes in their 
immunostimulatory and immuno-suppressive properties. To this end, intratumoral CD11b+ 
cells were first sorted by FACS to separate the CD11b+Ly6G+ neutrophils and 
CD11b+Ly6G- monocytes/macrophages. The purity of the isolated populations was found to 
be >90% following isolation (Figure 3.9A). To study the phenotypic changes in the 
neutrophils and macrophages following zoledronate treatment, real-time RT-PCR analyses 
of selected enzymes and cytokines were performed on these isolated populations. These 
analyses revealed that zoledronate treatment affected expression of immunomodulatory 
genes, particularly in the neutrophil rather than in the macrophage subset of tumor 
infiltrating myeloid cells. As shown in Fig. 3.9B, with the exception of iNOS, the 
monocyte/macrophages subset from zoledronate-treated tumors did not exhibit alterations 
in the message levels of immunostimulatory or immunosuppressive mediators, whereas the 
neutrophils showed a more pro-inflammatory and immunostimulatory phenotype.  
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A.  
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Zoledronate promotes an inflammatory and immunogenic gene expression profile 
specifically in neutrophil subset of myeloid cells (A) Neutrophil (CD11b+Ly6G+) and 
monocyte/macrophage (CD11b+Ly6G-) subsets of myeloid cells were isolated from zoledronate 
treated and untreated LLC tumors (n=6 per group). A representative flow cytometry analysis of 
CD11b+Ly6G+ and CD11b+Ly6G- cells before and after sorting is shown. (B) Isolated cell 
populations were subjected to gene expression analysis by real-time PCR for the representative 
M1/M2 or N1/N2 chemokines and cytokines. Results were normalized to β-actin levels. Fold 
change of each factor was calculated using the expression level in the untreated control cell 
population as the denominator. Data are representative of 3 independent experiments. The 
significance was determined by one-sample t-test (*p<0.05, **p<0.01, ***p<0.001). 
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In this context, expression levels of the immunosuppressive factors IL-10 and 
arginase were found to be significantly reduced while levels of the pro-inflammatory and 
immunostimulatory mediators iNOS, IL-12 and TNF-α were increased in neutrophils from 
zoledronate-treated tumors. Overall, zoledronate skews neutrophil, but not macrophage, 
subset polarization away from the N2- to the N1-like phenotype. These findings signify 
those immunostimulatory, N1 activated neutrophils to be potential mediators of 
zoledronate-induced antitumor activity.  
3.7 Depletion of neutrophils abolishes the growth inhibitory effect of zoledronate 
Having ascertained the increased infiltration and anti-tumorigenic activation of 
neutrophils in treated tumors, the functional importance of these cells in mediating 
zoledronate-induced growth reduction was tested by depleting Ly6G+ cells in LLC tumor-
bearing animals. The LLC tumor model was selected due to its higher abundance of 
intratumoral neutrophils that corrolates with the stronger growth inhibitory effect of 
zoledronate in this model compared to MC38 and B16 models (cf. Figures 3.1 and 3.2). 
Neutrophils were depleted in both treated and untreated tumor-bearing animals by using an 
i.p. administered neutrophil-specific anti-Ly6G antibody219 (Figure 3.10A). Tumor growth 
was compared with that in the control groups which were treated with a nonspecific isotype 
antibody. Efficiency of depletion was determined by analyzing blood and tumor samples 
from treated and untreated animals by flow cytometry. Intraperitoneal administration of the 
anti-Ly6G antibody caused depletion of approximately 90% of neutrophils from blood and 
tumors (Figure 3.10B). Isotype-matched control antibodies had no effect on tumor growth 
in control mice. As discussed previously, tumor infiltrating neutrophils in general support 
tumor growth, and predictably, elimination of neutrophils in untreated control mice resulted 
in a modest, but non-significant, reduction in tumor growth suggesting that neutrophils 
from untreated tumors predominantly had a N2-like tumor-promoting phenotype in these 
conditions. However, depletion of neutrophils in zoledronate-treated mice caused a 
significant reversal of the growth inhibition induced by the drug. The difference in tumor 
growth between control and zoledronate-treated mice was no longer observed when mice 
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were treated with anti Ly6G antibodies (Figure 3.10C). These results corroborate the 
essential role of neutrophils in zoledronate mediated tumor growth inhibition.  
A.  .
                  
 
 
 
 
B. 
           
 
 
 
 
 
C.  
 
 
 
 
 
 
 
 
Figure 3.10: Influence of neutrophil depletion on LLC tumor growth and on growth response 
to zoledronate treatment. Mice bearing LLC tumors were divided into four groups (5-6 
mice/group) and treated as follows: no treatment; administration of anti-LyG Ab; zoledronate 
treatment only; and zoledronate treatment in combination with anti-Ly6G Ab. (A) 100 µg of the 
anti-Ly6G monoclonal antibody (1A8) was first applied one day before the initiation zoledronate 
treatment and then twice a week over the course of the experiment. The groups not treated with 1A8 
received an isotype-matched control antibody at the same schedule and dose. All treatments were 
applied intraperitoneally. (B) At the end of treatment, neutrophil depletion was confirmed by flow 
cytometric analysis. In (C) the differences in mean tumor size ± SEM (left panel) and tumor sizes 
of individual mice (right panel) with or without Ly6G depletion (α-Ly6G) in zoledronate treated or 
untreated mice are shown. Data are representative of 2 independent experiments.   
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3.8 Systemic administration of TGF-β reverses anti-tumor effects of zoledronate  
 As mentioned before, growing tumors induce resorption of bone that in turn results 
in release of active TGF-β, thus further stimulating tumor growth. In conjunction, a few 
studies have shown that bisphosphonates reduce bone derived TGF-β release by inhibiting 
osteoclast mediated bone resorption. Recent findings highlight the importance of TGF-β 
signaling in modulation of the immune cells in the tumor microenvironment and in 
orchestration of tumor development.221,222  It is known that ablation of carcinoma cell-
specific TGF-β signaling leads to increased myeloid cell infiltrates in the tumor 
microenvironment.223,224 This recruitment was correlated with increased expression of the 
chemokines CXCL1 and CXCL5 in the TGF-β signaling deficient tumor tissue.63,225 
Subsequent studies showed that systemic inhibition of TGF-β in tumor-bearing mice led to 
an influx of neutrophils into tumors. Furthermore, under TGF-β inhibiting conditions in 
vivo, neutrophils were shown to acquire an anti-tumor N1 phenotype.60 It is notable that the 
characteristics described above for conditions of TGF-β deficiency bear striking 
resemblances to those we have identified for zoledronate-treated tumors in the course of 
our studies.Therefore we next aimed to investigate the relevance of TGF-β in zoledronate 
driven changes in the tumor microenvironment and tumor growth by first examining the 
effect of zoledronate treatment on systemic TGF-β levels in LLC tumor-bearing animals.  
To this end, levels of TGF-β1 were measured in blood plasma samples collected from 
treated and untreated tumor-bearing mice. As shown in Figure 3.11A, zoledronate treatment 
induced only a modest and non-significant decrease in the level of systemic TGF-β1. 
Modulations in bone and plasma TGF-β levels are known to be subtle and/or transitional 
and therefore, detection would require repetitive measurements using more sensitive 
detection methods.226  Nevertheless, these transitional and/or subtle changes in TGF-β 
levels can affect downstream signaling that is important for neutrophil function, and 
thereby could be consequential in determining the effect of zoledronate. For these reasons, 
we went on to employ an indirect approach to assessing TGF-β significance, by 
determining whether supplementation of recombinant TGF-β (rTGF-β) to zoledronate-
treated animals would reverse the effects of the drug. Tumor-bearing animals were left 
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untreated or treated with zoledronate with or without rTGF-β administration. We first 
evaluated tumor growth under the influence of TGF-β and assessed the influence of TGF-β 
on the antitumorigenic effects of zoledronate. Administration of rTGF-β had no effects on 
animal health as well as tumor growth pattern in control group. However, administration of 
rTGF-β in zoledronate-treated animals abolished the growth inhibitory effect of zoledronate 
(Figure 3.11B-C). Since we had shown that zoledronate-induced growth inhibition is 
mediated by neutrophils we next asked whether neutrophil infiltration was also affected by 
TGF-β. As shown in Figure 3.11D, rTGF-β administration also reduced the frequency of 
neutrophils in tumors treated with zoledronate to a level comparable to control tumors. 
These results not only suggest the possible involvement of TGF-β in zoledronate-induced 
neutrophil infiltration but also support the hypothesis that neutrophils are important for the 
effects mediated by zoledronate in these tumor models. To validate further the influence of 
TGF-β in neutrophil infiltration of tumors in zoledronate-treated animals, in vitro assays 
were conducted. Given that zoledronate induces increased expression of neutrophil 
chemoattractants in LLC cells (see Figure 3.7), we tested whether TGF-β could suppress 
the zoledronate-induced neutrophil chemoattractant expression in these cells. In this regard, 
LLC cells in culture were either left untreated or treated either with zoledronate alone or in 
combination with rTGF-β. Quantitative RT-PCR analysis showed that while zoledronate 
treatment increased the expression of neutrophil chemoattractants in LLC cells, rTGF-β 
supplementation significantly attenuated the effect of zoledronate with regard to up-
regulation of CXCL1, CCL3 and CXCL5 expression (Figure 3.11E). Thus, this suppression 
of chemokine expression by supplementation with TGF-β suggests that impairment in 
TGF-β signaling would results in an enhancement of chemokine expression.  
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Figure 3.11: Systemic rTGF-β administration abrogates the effects of zoledronate on tumor 
growth and neutrophil infiltration. (A) Mean plasma TGF-β1 levels in LLC tumor bearing 
untreated and treated mice (n=8/group). Blood was collected 24 hours after the last treatment and 
TGF-β1 levels were measured as described in Materials and Methods. (B) Mice bearing LLC 
tumors were divided into four groups (n=8/group) and treated as follows: no treatment; rTGF-β; 
zoledronate only; and zoledronate in combination with rTGF-β. rTGF-β was administered i.p. three 
times per week at a dose of 100 ng/mouse. Comparison of mean tumor volume ±SEM 
administration is shown. (C) Fold changes in tumor volume ±SEM that was calculated as ratio of 
volume on treatment day 19 divided by volume on treatment day 1. (D) Flow cytometry was 
performed on digested tumors. The graph summarizes the percentage of Ly6G+ cells out of all 
tumor cells. (E) TGF-β suppresses zoledronate-induced CXCL1, CCL3 and CXCL5 expression in 
LLC cells in vitro. Cultured LLC cells were either left untreated or treated with 10μM of 
zoledronate alone or in combination with rTGF-β (10 ng/ml) for 16 hours. Real-time PCR was 
performed and relative mRNA levels were calculated using the standard 2−ΔΔct method227; 
normalized to the levels of the β-actin mRNA and reported as mean ± SEM. Statistical significance 
was assessed by two-sided Student’s t-test.   
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3.9 Blocking TGF-β enhances in vitro migratory properties of neutrophils  
To further validate the influence of TGF-β on neutrophil migration in zoledronate-
treated animals, an in vitro migration assay was conducted using LLC cancer cell 
conditioned medium as chemoattractant. Neutrophils isolated from none marrow of non-
tumor bearing naïve mice were utilized for testing the effect of reduced TGF-β 
concentrations on the migratory abilities of neutrophils. Since serum contains very high 
levels of TGF-β, the levels in serum of neutrophil growth media were titrated by using 
increasing amounts of TGF-β neutralizing antibody. After overnight incubation at varying 
levels of TGF-β neutralizing antibody, neutrophils were seeded in transwells in order to test 
their migratory capabilities towards cancer conditioned medium. Interestingly, the 
chemotactic migration of neutrophils increased in direct proportion to increasing amounts 
of TGF-β neutralizing antibody, suggesting that neutrophils under low TGF-β 
concentrations are more responsive to chemotactic signals. Neutrophil migration was 
further increased in transwells containing conditioned medium obtained from zoledronate-
treated LLC cells (Figure 3.12). These results are helpful in explaining the reduced 
numbers of neutrophils observed in tumors treated with rTGF-β in conjunction with 
zoledronate, in comparison to those treated with zoledronate alone.  
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Figure 3.12: Neutrophils cultured under reduced TGF-β concentration conditions 
exhibited improved migratory abilities. GFP expressing neutrophils were isolated from bone 
marrow of MacGreen mice as described in Materials and Methods section and cultured in media 
(DMEM-2.5% FCS, G-CSF 100ng/ml, M-CSF 5ng/ml) supplemented with 2.5, 5 or 10 μg/ml anti-
TGF-β antibody or its isotype control for 16 hours. Cell migration was assayed using transwell 
chambers containing 3μΜ pore-size membranes. Neutrophils (1x105) previously treated with 
different concentrations of TGF-β inhibitor antibody were seeded to the upper chamber.  The lower 
chamber was filled with conditioned medium from LLC cells treated without (LLC CM) or with 
zoledronate (zol-treated LLC CM) at a concentration of 10 μΜ. After 4 hours, percentage of 
migrating cells was scored by measuring the intrinsic GFP signals emitted by neutrophils on the 
undersurface of the polycarbonate membranes. The percentage of migrating cells was determined 
relative to the control (isotype Ab treated neutrophils). Data are the means ± SEM of three 
independent experiments. Statistical significance was assessed by two-sided Student’s t-test.   
 
3.10 Antitumor effects of zoledronate is augmented by liposomal encapsulation  
As shown in the initial studies described above, zoledronate demonstrated a 
statistically significant but modest in vivo antitumor effect in the chosen tumor models. The 
limited antitumor efficacy of zoledronate in vivo could be due to its rapid clearance from 
the blood as well as its high and preferential localization in bone. For these reasons, 
therapeutically effective serum levels of zoledronate may be difficult to achieve. Therefore, 
the anti-cancer activities of zoledronate may be inadequate in cases of cancers occuring 
outside of bone tissues. In an attempt to increase the plasma half-life and to improve tumor 
delivery of the drug, we encapsulated zoledronate in liposomes. Antitumor activity of 
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liposome encapsulated zoledronate (zoledrolip) on LLC tumors was evaluated in 
comparison to free zoledronate and empty liposomes that were used as an additional control 
for zoledrolip. LLC tumor-bearing mice were treated with comparable amounts of 
zoledronate in either free form or as zoledrolip. It is important to note that none of these 
agents was found to cause any significant changes in body weight, toxic adverse events or 
animal deaths. After five individual treatments, resulting in a total dose of 15 μg 
zoledronate per mouse the average tumor sizes in the free zoledronate treated group was 
reduced by 40% compared to those in the untreated control group.  On the other hand, in 
zoledrolip treated animals, average tumor size was 55% smaller compared to standart 
untreated control group, and 40% smaller than in the control group receiving empty 
liposomes (Figure 3.13A). Similar reductions in tumor size were achieved in MC38 tumor-
bearing mice upon zoledrolip treatment (Figure 3.13B). Liposomal encapsulation of 
zoledronate significantly improved the tumor growth-inhibiting effect of the drug. Notably, 
administration of empty liposomes also inhibited tumor growth significantly. It is known 
that plain liposomes can instigate a transient inflammatory reaction, thereby causing a 
partial reduction of tumor growth. However, use of liposomes alone did not account for the 
improvement in growth-inhibiting effect observed for zoledrolip compared to free 
zoledronate.  
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Figure 3.13: Antitumor activity of liposome encapsulated zoledronate on LLC and MC38 
tumors. Female C57/BL6 mice were s.c. inoculated with LLC or MC38 cells (5x105) suspended in 
50 µl HBSS. When tumors had reached a volume of 50 mm3, animals (n=6-8 per group) were 
treated with zoledronate (3µg i.p. per mouse) or with the same concentration of zoledrolip (ZL) (2.4 
µl of 1.25 mg/ml zoledronate containing liposomes) or empty liposomes (EL) as controls starting at 
day 7 and given every other day until sacrifice. Tumor size was measured every second day. (A) 
LLC tumor growth expressed as mean tumor volumes ±SEM (left panel) and as the fold changes of 
tumor volume relative to the first measurement at day 7 (right panel). (B) Growth of MC38 tumors 
expressed as mean tumor volumes ±SEM. Data were pooled from two independent experiments 
(n=6-8 mice per group). 
 
To determine whether the similar mechanisms of free zoledronate mediated growth 
reduction apply to zoledrolip, animals treated with zoledrolip were examined for the 
previously observed effects of the free drug. Therefore we first tested the potential anti-
angiogenic properties of zoledrolip in the LLC and MC38 tumor models which differ in 
their sensitivity towards anti-angiogenic drugs. Briefly, MC38 is known to be sensitive 
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whereas LLC is known to be resistant to anti-angiogenic treatments that employ an anti-
VEGF antibody.93 As expected, a divergent effect of zoledrolip was noted in the two tumor 
models. We found zoledrolip to be highly effective in inhibiting angiogenesis in MC-38 
tumors. However, in concurrence with free zoledronate, zoledrolip did not have significant 
effect on angiogenesis in LLC tumors, further corroborating previous reports that LLC 
tumors are not affected by reduced VEGF bioavailability (Figure 3.14A). Since 
angiogenesis inhibition does not explain the zoledrolip-induced growth reduction in LLC 
tumors, we explored whether zoledrolip could also exert antitumor effects through 
modulation of infiltration and polarization of neutrophils, as free zoledronate does. 
 For this purpose, neutrophil infiltration into LLC tumors was examined in digested 
tumor tissue samples. In line with free zoledronate treatment, zoledrolip-treated tumors 
were also infiltrated with higher numbers of neutrophils in comparison to empty liposome 
treated tumors (Figure 3.14B). Furthermore, neutrophils isolated from zoledrolip-treated 
tumors exhibited a more immunostimulatory phenotype (Figure 3.14C). Accordingly, 
depletion of neutrophils in zoledrolip treated mice rendered zoledrolip ineffective in 
restricting tumor growth (Figure 3.14D). In contrast, whereas empty liposomes impaired 
tumor growth to a certain extent, neutrophil depletion had no observable effect on tumor 
growth in empty liposome-treated mice, suggesting that empty liposomes influence tumor 
growth by different, independent mechanisms. Although no measurable changes were 
detected in the plasma levels of TGF-β in zoledrolip-treated mice, rTGF-β administration in 
zoledrolip treated mice resulted in reversal of the zoledrolip mediated tumor growth 
reduction (Figure 3.14E). These results suggest that free zoledronate and zoledrolip employ 
similar mechanisms to impair tumor growth in LLC tumors. The enhanced anti-tumor 
efficacy of zoledrolip can be explained by changes in the pharmacokinetic properties, the 
organ distribution and tumor accumulation of the drug, compared to the free from. In this 
regard, the biodistribution of 14C-labeled zoledronate and zoledrolip was analyzed in LLC 
tumor bearing mice. A significant difference was found in the distribution of zoledronate in 
tumors after i.v. injection of different drug forms. As shown in Figure 3.14F zoledrolip 
accumulated at a 10-fold higher amount in tumors as compared to free zoledronate. 
Furthermore, zoledrolip exhibited considerably prolonged circulation time in blood.  
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Figure 3.14:Liposomal formulation of the drug functions through similar mechanisms 
to delay tumor growth. (A)Tumors excised from untreated animals and animals treated with 
empty liposome or zoledrolip were embedded in paraffin, sectioned, and subjected to IHC. 
Angiogenic status was examined on LLC and MC38 sections. Representative images of CD31 IHC 
(left panels).  Right panels depict mean numbers of vessels per field ±SEM (×100 magnification). 
Microvessels were counted in five randomly selected fields of tumors from four mice of each group. 
(B) Flow cytometry was performed on digested LLC tumors extracted from untreated animals and 
animals treated with relevant reagents. The percentage of CD11b+ Ly6G+ cells out of all tumor cells 
in all treatment groups (n=8-10 mice/group) is shown. (C) Neutrophils (CD11b+Ly6G+) and 
monocytes/macrophages (CD11b+Ly6G-) were isolated from zoledrolip treated and untreated 
tumors.  Isolated cell populations were subjected to gene expression analysis by real-time PCR for 
the representative M1/M2 or N1/N2 factors. Fold change of each factor was calculated using the 
expression levels in untreated control cell populations as the denominator. Data are representative 
of 2 independent experiments. (D) Mice bearing LLC tumors were divided into four groups (n=6/ 
group), and treated as follows: empty liposomes; empty liposomes in combination with anti-LyG 
Ab (1A8); zoledrolip; and zoledrolip in combination with anti-Ly6G Ab. Animals were treated as 
described in the legend of Figure 3.10. Graphs depict the differences in mean tumor size ± SEM 
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(left panel) and tumor size of individual mice (right panel) from each group. Data are representative 
of 2 independent experiments. (E) Mice bearing LLC tumors were divided into four groups (6 
mice/group), either no treatment or treated as follows; administration of rTGF-β; zoledronate only; 
and zoledronate in combination with rTGF-β. Treatments were done as described in the legend to 
Figure 3.11. Tumor growth rates of LLC tumor bearing individual animals is presented as fold 
changes of tumor volume against the first measurement at day 7. The significance was determined 
by two-sided student’s t-test. (*p<0.05, **p<0.01) (F) LLC tumor bearing mice were administrated 
with 14C-labeled zoledronate or zoledrolip intravenously. Animals were euthanized 24 h after i.v. 
administration; organs were removed, digested and processed as described in Materials and 
Methods (unpublished results R. Schwendener). 
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4. DISCUSSION AND OUTLOOK 
The therapeutic efficacy of a cancer drug is heavily dependent upon the tumor 
microenvironment. In most cases, the tumor microenvironment is largely influenced by 
myeloid cells, in particular neutrophils and macrophages, which are known to augment 
tumor growth and also to confer drug resistance.36 Therefore, modulation of myeloid cell 
properties can be valuable in restricting malignant tumor growth as well as in improving the 
therapeutic efficacy of conventional drugs. This study has presented the novel in vivo 
immunomodulatory property of zoledronate. We demonstrated that the drug restricts tumor 
growth by modulating the anticancer immune response. Our major finding is the ability of 
zoledronate to skew neutrophil polarization from the immunosuppressive pro-tumorigenic 
N2-like phenotype to the immunostimulatory anti-tumorigenic N1-like phenotype.   
4.1 In vivo antitumor activity of zoledronate in syngeneic mouse tumor models  
  Due to its osteoclast inhibitory activity, zoledronate has become widely used in 
oncology for the treatment and prevention of cancer-related bone diseases as well as bone 
metastases.208 To date, zoledronate research in cancer has largely focused on its effects on 
primary tumors located in bone and on the formation of bone metastases. Adjuvant 
zoledronate treatment has been reported to improve the 1-year survival rate for breast, 
prostate and bladder cancers which are the most common primary cancers that metastasize 
to the bones.209,228,229 Prolonged survival of zoledronate-treated patients was generally 
attributed to a reduction in bone metastasis, a result of the anti-bone resorption properties of 
the drug. Whether clinically relevant doses of zoledronate can exert antitumor activities on 
primary tumors and metastases occurring in tissues other than bone is not conclusively 
understood at present. 
There are only a few recent studies describing the effects of zoledronate on growth 
of soft tissue tumors.176,230-233 In these animal studies, zoledronate was generally used at 
doses higher than recommended in the clinical practice. Thus, it remains important to 
determine if a clinically relevant dosing regimen of zoledronate can achieve meaningful 
antitumor effects in animal models of soft tissue tumors. In this study, we treated female  
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immunocompetent C57BL/6 mice bearing syngeneic subcutaneous tumors with 
zoledronate, examining whether the drug has an impact on the growth of primary tumors in 
tissue other than bone. The zoledronate dosage given (150 μg/kg every second day for 2 
weeks) was adapted from pharmacokinetic data of cancer patients receiving the equivalent 
standard clinical dose.210 Although zoledronate is administered intravenously on a monthly 
regimen in humans, several studies suggested that it is best supplied on a daily regimen in 
mice, reflecting differences in pharmacokinetics.176 Our results show that zoledronate at 
doses equivalent to those approved for clinical use significantly reduces the growth of LLC 
and MC38 tumors but not B16 tumors.  
Seeking to investigate the mechanistic basis of the reduced tumor growth, we 
assessed the frequency of apoptosis and found increased numbers of apoptotic cells in 
zoledronate treated tumors, while tumor cell proliferation itself was not affected. 
Zoledronate does not appear to act as an antimitotic drug. Collectively, these data suggest 
that the biological effects of zoledronate result from increased apoptosis in tumor cells. It is 
very unlikely that zoledronate has a direct effect on cancer cell survival, since cytotoxic 
concentrations of the drug are difficult to achieve in tumors in vivo. In cancer patients, 
following i.v. administration of a standard 4 mg dose of zoledronate,  peak plasma levels 
are estimated to be 1–2 µM.168 According to pharmacokinetic studies in mice, animals 
treated with zoledronate at 150μg/kg are expected to reach peak serum concentrations of 
about 1-3 µM.234,235 Kuroda et al reported that 20 to 30 µM zoledronate was required in 
vitro over 24 to 48 hours to induce apoptosis in BV173 (Pre-B acute leukemia cell line) 
cells.231 Other reports have shown zoledronate manifesting a direct antitumor activity in 
vitro at even higher concentrations which ranged from 50 μM to 1 mM, concentrations that 
are 25 to 500 times higher than those achievable in vivo.211,212 Obviously, the achievable 
circulating concentrations of free zoledronate are too low to exert a direct pro-apoptotic 
effect on cancer cells.  
In regard to other potential targets of zoledronate action, we tested whether the 
increased apoptosis in treated tumors is due to impaired angiogenesis, and indeed, anti-
angiogenic properties of the compound were reported in a number of studies. Santini et al  
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and others showed that systemic and intratumoral VEGF levels were lowered following 
zoledronate administration.236 Giraudo and colleagues reported that reduced VEGF 
availability upon zoledronate treatment impairs angiogenesis and tumor growth in cervical 
cancer.176 Although we observed similar reductions in VEGF expression in myeloid cells 
isolated from zoledronate-treated tumors, the free drug was ineffective in inhibiting 
angiogenesis in either tumor type. However, it must be noted that our data are based on 
end-of-study analysis and so we cannot exclude the possibility of temporal changes in 
microvascular density during tumor growth which might also affect overall tumor growth 
rate. Furthermore, without affecting the number of vessels, it is possible that zoledronate 
may alter structure and function of blood vessels in tumors. These parameters should also 
be analyzed in further studies. 
4.2 Zoledronate impairs tumor growth by interfering with neutrophil support 
In regard to potential cellular targets of zoledronate action, we cannot exclude the 
possibility that due to their high endocytic activity myeloid cells are in a privileged position 
to take up zoledronate, even at low concentrations. It is intriguing that although we 
observed a substantial increase in the number of infiltrating neutrophils, the frequency of 
other myeloid cells was not appreciably altered. Notably, increases in neutrophils were 
found in blood, spleen and peritoneum but not in bone marrow, suggesting that this effect 
does not result from increased generation of neutrophils in bone marrow but rather through 
their increased release from bone marrow following augmented production of neutrophil 
chemoattractants. In this regard our data show that zoledronate increased the expression of 
major neutrophil chemoattractants within the tumor that may lead to increased recruitment 
of these cells into tumors. In vitro data further confirm that, zoledronate can directly induce 
the increased expression of these chemokines in cancer cells. On the other hand, it remains 
to be resolved whether the higher abundance of neutrophils in treated tumors is also 
associated with an increased life-span of these cells. 
There is an increasing interest in elucidating the role of neutrophils in tumor 
progression, with various evidences implicating them in either promoting or inhibiting 
tumor growth and spread. Recently, the contradictory role of neutrophils in both tumor  
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suppression and promotion was re-evaluated in terms of the characterization of different 
types of tumor-associated neutrophils with polarized N1 or N2 phenotypes.60 Referencing 
these studies, further phenotypic analyses of these cells revealed that neutrophils from 
zoledronate-treated mice exhibited an antitumor activated phenotype. Tumor-infiltrating 
neutrophils from untreated control animals were found to adopt an N2 phenotype that is 
characterized by the higher expression of the immunosuppressive factors IL-10, VEGF, 
TGF-β along with lower levels of immunostimulatory factors such as IL-12. Note that 
VEGF is a molecule exhibiting a dual profile as apart from its well-known pro-angiogenic 
function, it also exerts immunosuppressive effects.237 Consistent with this N2 phenotype, 
depletion of the pro-tumorigenic neutrophils delayed tumor growth in untreated mice. 
Conversely, neutrophils from zoledronate-treated mice exhibited the opposing N1 
phenotype, with higher levels of IL-12 and lower levels of IL-10 and TGF-β.  Furthermore, 
discrimination between pro- and anti-tumorigenic activated neutrophils was also performed 
based on their differential L-arginine metabolism via arginase and iNOS (see Figure 3.9). 
Nitric oxide synthases (NOS) are important in the metabolism of L-arginine to NO, an 
critical mediator in inflammation and immune reactions, while arginase can convert L-
arginine to urea and L-ornithine, a suppressor of cytotoxic T lymphocyte activity as well as 
a precursor of the polyamines spermine and spermidine that can act as tumor growth 
factors.238 Transcription of iNOS is known to be increased in antitumor activated myeloid 
cells, resulting in prolonged high levels of NO production.239 The iNOS enzyme has been 
directly implicated in macrophage-mediated tumoricidal activity and several studies have 
demonstrated that NO donors are cytotoxic and pro-apoptotic to tumor cells.240 In our 
experiments, neutrophils from tumors of zoledronate-treated mice exhibited upregulation of 
iNOS, along with reduced expression of the immunosuppressive factor arginase. Therefore, 
we further speculate that the observed higher expression of iNOS in neutrophils isolated 
from zoledronate-treated tumors might be accompanied with significant tumor cytotoxicity.  
Our findings are supported by a recent report claiming tumor associated 
macrophages as the most important immune targets of zoledronate-mediated antitumor 
activity.178  In agreement with our results regarding myeloid cell polarization, these authors 
showed that zoledronate treatment in vivo induced higher iNOS expression, concomitant  
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with enhanced NO production in CD11b+ cells isolated from the peritoneum of animals 
bearing mammary tumors. In addition, reduced IL-10 and enhanced IFN-γ levels were 
observed in the stroma of zoledronate-treated mammary tumors. 258 However, in our study 
we dissected the CD11b+ population into Ly6G+ (neutrophil) and Ly6G-
(monocyte/macrophage) subsets and revealed that zoledronate induces changes in the 
activation status of neutrophil, but not macrophage, subsets of CD11b+ myeloid cells. 
Although macrophages from treated tumors do exhibit upregulated expression of iNOS, 
they do not exhibit a fully repolarized phenotype.   
Gene expression signatures reflecting a more tumor-cytotoxic N1 phenotype for 
neutrophils of zoledronate-treated animals suggest a potential role for these cells in 
zoledronate-induced tumor growth inhibition. Depletion of neutrophils in zoledronate-
treated mice reversed the antitumor effect of treatment, while augmenting tumor growth in 
untreated mice (see Figure 3.10). These results confirm the critical role of neutrophils in 
zoledronate-induced antitumor activity. Additionally, the differences exhibited under 
zoledronate treated and untreated conditions in terms of tumor growth response to Ly6G 
depletion reflect the presence of different phenotypes of tumor-associated neutrophils in 
each condition. 
Another finding that points towards the importance of neutrophils in zoledronate-
induced antitumor effects is the correlation between abundance of neutrophils in tumors 
and the ability of the tumors to respond to zoledronate treatment.  In tumors, such as LLC 
and MC38, with a relatively high infiltrate of neutrophils (approximately 2 % of total tumor 
cells), zoledronate delayed tumor growth significantly, but in tumors like B16 that lack 
significant neutrophil infiltration (approximately 0.2 % of total tumor cells), zoledronate 
had a slight but insignifiant antitumor effect. 
As our findings were comparable in two different tumor types (LLC and MC38), we 
suggest that N1 polarization could be a general response of the tumor microenvironment 
following zoledronate treatment. Having illustrated the ability of zoledronate to directly or 
indirectly influence neutrophils to assume an antitumor phenotype, our study supports the 
idea that neutrophil function can be tailored in vivo to achieve an enhanced antitumor 
immune response.  
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These results are likely to be relevant to human cancers. A recent study by Gnant et 
al.209 showed that a significant increase in disease-free survival was recorded in women 
with early stage breast cancer after treatment with zoledronate in combination with 
aromatase and tamoxifen as compared with patients treated with tamoxifen and aromatase 
alone. Given that neutrophil-derived factors are known to be critical in the progression and 
metastasis of human breast cancer, the clinical efficacy of zoledronate could be ascribed to 
its ability to re-polarize the neutrophils in the tumor microenvironment.241 
4.3 TGF-β complementation reduces therapeutic efficacy of zoledronate    
The identification of neutrophils as the significant anticancer cell type in 
zoledronate treated tumors is an exciting finding, due to the accumulating evidences 
regarding their tumoricidal properties which can be further enhanced by inhibition of TGF-
β signaling. TGF-β is often overexpressed by tumors and plays a major role in regulating 
migration242 and function61 of neutrophils in tumors. Recent studies showed that inhibition 
of the TGF-β signaling pathway increases the recruitment of neutrophils in cancer and in 
some types of chronic disease states.60,243 Neutrophils isolated from tumors of TGF-β 
receptor-blocked mice were shown to exhibit a pro-inflammatory phenotype that is 
strikingly similar to the phenotype of neutrophils in zoledronate-treated mice.60 These 
findings correlate closely with our own observations in relation to the zoledronate-induced 
pro-inflammatory phenotype as well as increased recruitment of neutrophils. On the basis 
of these similarities between the effects of TGF-β inhibitors and zoledronate, we 
hypothesized that zoledronate could modulate neutrophil migration and/or function through 
altered TGF-β signaling. Our hypothesis is further supported by the recently reported 
application of bisphosphonates in alleviating skeletal-related pathologies in cancer, 
including bone metastasis, which coincides with a reduction in TGF-β signaling 
activity200,244. It is known that TGF-β is sequestered at high levels in bone matrix and that 
inflammatory cytokines, as major mediators of osteolysis, can modulate TGF-β 
bioavailability 245-247. Primary tumors or those metastasized to bone can stimulate 
osteoclast-mediated osteolysis by increasing the levels of parathyroid hormone-like protein 
and RANKL 207,248,249. The increased bioavailability of TGF-β in bone caused by osteolysis  
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can strongly influence the phenotype of developing neutrophils and their migratory 
capabilities. Moreover, we found that only a very low amount of zoledronate reaches the 
tumor tissue and so is unlikely to directly affect tumor cells, whereas the majority of the 
drug reaches the bone (see Figure 3.14G). As an effective inhibitor of osteoclast activity, 
zoledronate may reverse tumor-induced hyperactivity of osteoclasts, thereby normalizing 
serum TGF-β levels in tumor-bearing mice. In fact, it was postulated previously that 
bisphosphonates could have an antitumor activity by altering the release of growth factors, 
particularly TGF-β, in the bone microenvironment.200 Therefore, we decided to look for 
paracrine mechanisms which might give rise to phenotypes associated with zoledronate 
treatment in mouse tumor models.  Due to the lack of sufficiently sensitive methods we 
could not analyze the direct modulation of TGF-β or its activity by zoledronate. 
Nevertheless, supplementation of zoledronate or zoledrolip with TGF-β reversed the 
zoledronate-induced enhanced recruitment of neutrophils and concomitantly restored tumor 
growth to levels similar to those in untreated controls (see Figures 3.11 and 3.14). These 
results imply that TGF-β dominates over zoledronate activity. Our in vitro results further 
support this hypothesis by revealing that upregulated expression of neutrophil 
chemoattractants induced by zoledronate treatment were reduced to control levels by 
supplementation with recombinant TGF-β (see Figure 3.11). It is also known that 
increasing TGF-β levels can deactivate myeloid cells by decreasing expression of critical 
transcription factor genes such as NFκB and STAT1.114 Therefore, it seems probable that 
the increased inflammatory activities of neutrophils in zoledronate-treated tumors are due 
to increased expression of these critical transcription factors.  
Since zoledronate mimics the effects of TGF-β signaling inhibitors, we propose that 
it can provide an alternative to the need for such signaling inhibitors. This notion is 
supported by a recent report showing that TGF-β repressed neutrophil migration by 
inhibiting expression and secretion of neutrophil chemoattractants in endothelial 242 and 
cancer cells63.  In addition, our in vitro migration experiments revealed that neutrophils 
sense chemotactic signals more strongly under reduced TGF-β levels. (see Figure 3.12) 
These results hint that TGF-β influences migration of neutrophils not only by regulating 
tumor-secreted chemoattractants, but also by directly influencing intrinsic migratory  
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abilities of these cell types. These intrinsic changes may very likely be due to modulation of 
cell surface receptors for chemokines or of transcriptional regulators of inflammation. It 
would be interesting to test whether zoledronate influences the neutrophil migration and 
gene expression signature by acting directly on these cells or if the observed effects are a 
combined action of zoledronate and/or reduced TGF-β levels.  
An important point that remains to be discussed is the role of adaptive immunity, 
especially of cytotoxic T cells in the effects caused by zoledronate. It is known that 
zoledronate can enhance the cytotoxic activity of the Vγ9/Vδ2 subset of γδT cells in cancer 
and that activated γδT cells can be used as cell-based therapy to treat cancer patients 191,250. 
However, a murine counterpart of the Vγ9/Vδ2 subset of γδT cells has so far not been 
identified. Previous studies did not find any evidence of γδT-cell recruitment in the 
peripheral blood or lymphoid organs of zoledronate-treated mice.250 Several studies 
demonstrated the ability of neutrophils to stimulate CD8+ T cell proliferation and activation 
in cancer. 134,251 This notion finds support in the immunoregulatory gene expression profile 
of neutrophils isolated from zoledronate-treated tumors which express high levels of IL-12 
and low levels of IL-10, VEGF and arginase. Downregulation of IL-10, arginase and VEGF 
in neutrophils is likely to reverse immunosuppressive effects on CD8 T cells. The pro-
inflammatory cytokine IL-12 induces production of IFN-γ by macrophages and NK cells, 
thus favoring differentiation of naïve CD4+ T cells into mature Th1 cells.252 Accordingly, 
our in vitro co-culture experiments, demonstrating enhanced proliferation and IFN-γ 
production of T cells which were co-cultured with CD11b+ cells from tumors of 
zoledronate-treated mice, confirm the immunostimulatory properties of these cells and also 
raise the question of the possible involvement of these CD8 T cells in zoledronate-induced 
antitumor effects (see Figure 3.6). However, we could not detect any significant increase in 
the frequency of CD8+ T cells in treated tumors. In fact, subcutaneous tumors have been 
shown to be refractory for cytotoxic T cell response, suggesting that zoledronate might be 
more effective in orthotopic tumor models, and gain more clinical value.253 Nevertheless, 
our results show promise in modulating the immune response in a wide variety of cancers 
by using zoledronate as adjuvant tumor therapy. On the basis of this study, we believe that 
the application of zoledronate in cancer therapy holds immense value and that further  
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efforts should be extended to identify the correct niches, combinations, and conditions in 
which this drug should be given to cancer patients.  
4.4 Liposomal encapsulation potentiates the antitumor effect of the zoledronate 
Stronger tumor growth inhibition was achieved by use of zoledrolip, suggesting                  
additive therapeutic effects of liposomes. This improved effect of zoledrolip may be either 
due to intrinsic properties of liposomes in activating inflammatory cell types and/or due to 
improved delivery of zoledronate via liposome. In fact we observed that empty liposomes 
exhibit some degree of tumor growth inhibition suggesting that liposomes can indeed 
induce a weak inflammatory response. Besides that, organ distribution studies done in our 
laboratory showed that liposomal encapsulation of zoledronate enhanced the accumulation 
of the drug in tumors (up to 1% of the injected dose of zoledrolip versus  0.1% of free 
zoledronate injection; unpublished results R.Schwendener; see Figure 3.14G) as well as in 
spleen and liver. The improved distribution of liposomal zoledronate into tumor tissues can 
be attributed to the prolonged circulation times and passive tumor targeting properties of 
liposomes.254 Previous studies have demonstrated that liposomes can extravasate through 
the fenestrated blood vessels that are typical of tumor neo-angiogenesis, and therefore 
accumulate at high concentrations in solid tumors.255 However, as spleen, liver and tumor 
have abundant phagocytic cell types, the increased drug accumulation may also reflect that 
liposomes are directing zoledronate to myeloid cell types in these tissues. Improved 
delivery of zoledronate to myeloid cells by liposomal formulations might result in a more 
pronounced antitumor phenotype that is responsible for stronger growth inhibition effects. 
Although free drug was ineffective at inhibiting angiogenesis in either tumor type, 
zoledrolip inhibited angiogenesis strongly in MC38 tumors but not in LLC tumors. This 
discrepancy in the responses of the tumor models to liposomal zoledronate corroborates 
with the previous reports that LLC tumors are not affected by reduced VEGF 
bioavailability. It is possible that redundancy of pro-angiogenic factors in LLC tumors can 
bypass the depletion of VEGF, perhaps through upregulation of other angiogenic factors 
such as FGF or angiopoietin-1 by tumor and stromal cells. In this respect, the use of the 
LLC tumor model, refractory to angiogenesis inhibitors, serves an important purpose in  
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dissecting novel mechanisms, independent from angiogenesis inhibition, that contribute to 
the therapeutic properties of zoledronate. 
4.5 Conclusion and Outlooks 
In conclusion, we showed that zoledronate, a relatively non-toxic drug currently 
marketed mainly for the treatment of osteoporosis and cancer-related skeletal events, is 
effective against experimental lung and colon carcinoma tumors. As summarized in Figure 
4.1, we proposed that the drug impairs tumor growth by modulating the tumor 
microenvironment as shown by an increased numbers of neutrophils and their reverted 
polarization from the N2 to N1 phenotype. Having identified neutrophils as cellular targets 
of the antitumor action of zoledronate, we contributed to the body of evidence that 
neutrophils and their secreted products are functionally important for the growth of a 
variety of tumors.  We further provide evidence that the use of exogenous modifiers to 
achieve re-orientation of these cells in favor of a more antitumoral phenotype is a 
promising anticancer strategy. Such an approach may improve the outcome of current 
immunotherapeutic strategies, which are counteracted by the potent immunosuppressive 
reactions in the tumor stroma. 
In this study, we highlight the TGF-β signaling pathway as a potential regulatory 
switch for the distinct migratory and phenotypic characteristics of neutrophils in 
zoledronate-treated animals. Further research is warranted to fully elucidate the role of 
TGF-β signaling in this process. In this context, establishment and implementation of in 
vivo reporter systems would help to detect zoledronate-induced transient changes in TGF-β 
signaling in neutrophils. Another potential underlying mechanism of this cytokine shift 
might be via STAT signaling, since a recent study in mice showed that amino-
bisphosphonates may prolong phosphorylation of STAT1, a key molecule in the 
polarization of macrophages towards an M1 phenotype.127 Further analysis of the molecular 
basis of the zoledronate-induced neutrophil phenotype will help to determine other 
potential signaling pathways responding to zoledronate. Identification of these pathways 
may allow us to selectively modulate the functional activities of neutrophils in cancer.   
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Figure 4.1: A schematic diagram showing the hypothetical antitumor mechanism of 
zoledronate and zoledrolip. Upon in vivo administration, zoledronate induces enhanced expression 
of neutrophil-attracting chemokines resulting in increased accumulation of neutrophils in tumors. In 
the tumor milieu, zoledronate skew neutrophil polarization away from their protumorigenic 
/immunosuppressive N2-like phenotype that is known to be regulated by TGF-β. Accordingly, 
TGF-β administration in treated animals reverse the anti-tumor effects of treatment. Free 
zoledronate primarily accumulates in bones while liposomal encapsulation of the drug improves its 
bioavailability in extraskeletal tumor sites that leads to stronger inhibition of tumor growth.  
 
Although the findings of this investigation are novel and important, some 
limitations should be addressed. Here we explored the effect of the drug on primary tumor 
growth. However, effects of drugs on primary tumor growth do not necessarily predict 
therapeutic outcome. Cancer-related deaths are caused principally by metastasis arising 
from residual disease, whose therapeutic responses have been suggested to be substantially 
different from those of primary tumors.  Future studies will be required to determine the 
specific contribution of zoledronate-induced activation of neutrophil functions in the 
migratory, invasive and metastatic features of tumor cells. As subcutaneously implanted  
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tumors rarely express invasive or metastatic phenotypes, these features cannot be evaluated 
in such models.  This issue could be overcome by studying these aspects in orthotopic or 
spontaneously growing tumor models. 
 
The promising antitumor efficacy of zoledrolip warrants further evaluation in  
combination therapy settings where zoledrolip is incorporated into conventional therapeutic 
regimens. In this respect, strategies encouraging the development of intense intratumoral 
neutrophil infiltrates may help to further improve the antitumor effect of zoledrolip. 
Recombinant G-CSF, a key regulator of neutrophil survival and production, is commonly 
used in clinics to accelerate recovery of neutrophil numbers in patients with chemotherapy-
induced neutropenia.256 However, G-CSF has recently been shown to diminish the anti-
tumor activity of chemotherapy, partially due to augmented angiogenesis induced by 
neutrophils, indicating pro-tumorigenic activation of these cells in tumors. In relation to this 
point, it is possible that addition of zoledronate or zoledrolip, when conventional 
chemotherapy is used in combination with G-CSF therapy, might alter that outcome by 
polarizing G-CSF-stimulated neutrophils to elicit antitumor activity. Given the good safety 
profile affirmed by its common use by postmenopausal women along with the growing 
appreciation of its therapeutic value, zoledronate holds great promise as an 
immunotherapeutic adjuvant in cancer therapy. 
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5. MATERIAL AND METHODS 
Antibodies and reagents 
All the anti-mouse antibodies used for flow cytometric analyses including APC 
conjugated Ly6G (1A8 clone), F4/80, CD8, Pacific Blue conjugated CD11b, CD11c, CD3, 
PE/Cy7 conjugated CD45 and IFN-γ were purchased from Biolegend (San Diego, CA). 
Primary antibodies for IHC analysis of frozen and paraffin sections were a goat polyclonal 
CD31 (Biolegend), a rabbit monoclonal cleaved caspase-3 (Cell Signaling Technology), a 
rabbit monoclonal phospho-histone H3 (Cell Signaling Technology), and a biotinylated 
anti-GFP (GeneTex). Secondary antibodies used were donkey-anti-rat-Cy5, bovine-anti-
goat-FITC, donkey-anti-rabbit-Cy5, and streptavidin Cy-5 (Jackson ImmunoResearch). The 
1A8 antibody (BioXCells) was used for the in vivo depletion of Ly6G+ cells and the rat 
IgG2a (2A3) antibody (BioXCell) was used as isotype control. Recombinant TGF-β1 
(rTGF-β) was purchased from R&D Biosystems. Fluorescent dye CFSE (5,6-
carboxyfluorescein diacetate succinimidyl ester) was purchased from Invitrogen (Carlsbad, 
CA, USA). Zoledronate was kindly provided by Novartis Pharma AG (Basel, Switzerland). 
Cells and animals 
The LL/2 Lewis lung carcinoma (LLC1) cell line was purchased from the European 
Collection of Cell Cultures (ECACC catalog no. 90020104), the B16 melanoma cell line 
(ATCC no. CRL-6323) was from American Type Culture Collection (ATTC; Rockville, 
MD). The MC38 colon adenocarcinoma cell line was kindly provided by Dr. L. Borsig, 
Institute of Physiology, University of Zurich, Switzerland. All cell lines were of C57BL/6 
mouse origin and were free of Mycoplasma and maintained in DMEM (Gibco) 
supplemented with 10% (v/v) heat-inactivated FCS (Gibco) and 0.8 % 
penicillin/streptomycin (Sigma-Aldrich). Cells were grown in monolayers at 37 ºC in a 
humidified CO2 incubator.  
 All experiments were done using 8- to 12- week- old female immunocompetent 
mice. Wild-type C57BL/6 mice were from Charles River Laboratories (Germany) and 
transgenic  mice  expressing  EGFP  under  the  control  of the  CSF-1R  (c-fms)  promoter,  
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referred to as MacGreen mice, were provided by Dr. D.A. Hume (Edinburgh, UK).213 Mice 
were kept under standard housing and dietary conditions at the University of Zurich animal 
facility. Animal studies were performed under license 215/2008 issued to R. Schwendener 
by the Veterinary Department of the Canton Zurich, Switzerland.  
Murine tumor models and treatments  
The syngeneic B16 melanoma, Lewis lung carcinoma and MC38 colon carcinoma 
tumor models were established by subcutaneous injection of 3 × 105 MC38 or B16 or 5 × 
105 LLC cells suspended in 50 μl HBSS into the right hind flank of C57BL/6 wild type or 
MacGreen mice. Tumors were allowed to grow for 5-8 days to reach a volume of 
approximately 50-70 mm3 before initiation of treatment. Once tumors had reached 
appropriate sizes, mice were randomly divided into treatment and control groups. The mice 
of treatment groups received the drugs by intraperitoneal injection as described in the 
legends of the corresponding figures (see Fig 3.1,2 and Fig 3.13). Control groups received 
an equal volume of HBSS or empty liposomes i.p. Treatment was repeated every 2nd day 
during the course of tumor growth. Tumor sizes were measured by a caliper every 2 to 3 
days and recorded as tumor volume calculated by the formula V=пLW2/6 (L: largest tumor 
diameter, W: perpendicular diameter). Growth was monitored until a tumor volume of 2 
cm3 was reached where after mice were sacrificed.  
In vivo depletion of Ly6G+ neutrophils 
For depletion of neutrophils, each mouse received 100 µg of anti-Ly6G mAb (clone 
1A8) i.p. in 100 µl HBSS. Control animals were injected with 100 µg of an isotype-
matched IgG2a Ab (2A3) i.p. in 100 µl HBSS/mouse. The dosages of the depletion and 
control Ab were chosen according to accepted use in the literature.60 Injections were started 
1 day before drug administration and applied repeatedly throughout the entire experimental 
period as shown in Fig. 3.10. Depletion was controlled by testing blood and tumor samples 
from treated mice by flow cytometric analysis.  
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Flow cytometric analysis of tumors, blood, spleen, peritoneal cells and bone marrow 
At the end of the treatment period tumor tissue, spleen, peritoneal lavage cells and 
blood samples were collected. Harvested tumors were minced and digested with a mixture 
of 2 mg/ml collagenase type IV, 2 mg/ml DNase I  and  500 U/mg hyaluronidase  (all from 
Sigma) at 37°C for 30 min. Dissociated tissues were passed through a cell strainer (70 µm 
mesh size). Dead cells and debris were removed using the dead cell removal kit (Miltenyi 
Biotech). Bone marrow cells were harvested from both femurs and tibias by flushing the 
bone cavity with RPMI using 25 gauge needles followed by centrifugation and 
resuspension in PBS. 
Harvested spleens were cut into 3 pieces. Splenocyte suspensions were prepared by 
gently meshing spleen pieces with the rubber end of a syringe plunger through the 70 µm 
mesh size strainer. Peritoneal cells were obtained by gently washing the peritoneal cavity 
with 10 ml cold PBS, then centrifuged and resuspended in PBS. Blood samples were 
collected in heparinized tubes (BD, Microtainer) directly from the heart by cardiac 
puncture.  
To eliminate red blood cells in tumors, blood, bone marrow and spleen, cell 
suspensions were centrifuged and the pellets resuspended in FACS lysing solution (BD 
Pharm Lyse) and incubated for 10 min at room temperature. Then cells were centrifuged at 
300 g for 5 min and washed two times with PBS containing 2% fetal bovine serum and 
0.05% sodium azide (FACS buffer). To prevent nonspecific binding, single cell 
suspensions were preincubated with Fc Blocker (anti-mouse CD16/32, BioLegend) for 10 
min on ice. Cells were then labeled with conjugated antibodies as listed above at 4 °C for 
30 min in the dark. Cell suspensions were centrifuged at 300 g for 5 min and washed with 
FACS buffer to remove residual antibodies. 
For intracellular IFN-γ staining, cells (106 cells/ml) were incubated in RPMI with 
5% FCS for 5 hours in the presence of Brefeldin A, ionomycin and PMA to stimulate the 
production of cytokines and to inhibit the secretion of the synthesized cytokines before 
addition of Fc blocker, fixation, and permeabilization.  
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All experiments were performed using a CyAn 9 ADP flow cytometer (Beckman-
Coulter). Data analysis was done using FlowJo software (Tree Star, Ashland, OR). 
Administration of exogenous TGF-β1 
Intraperitoneal injections of recombinant TGF-β1 at a dose of 1µg /mouse were 
started 2 days after the first zoledronate treatment and repeated two times per week during 
the course of tumor growth.  
Isolation of Ly6G+, CD11b+ and GFP+ cells 
Twenty four hours after the last treatment, animals were euthanized and tumors 
were harvested. To isolate Ly6G and CD11b cells, tumors were digested and single cell 
suspensions were prepared as described. CD11b+Ly6G+ and CD11b+Ly6G- cells were 
sorted using FACS Aria cell sorter (BD Bioscience). CD8 T cells were isolated from 
spleens of naïve mice by using the CD8a T cell isolation kit with LS columns (Miltenyi 
Biotec) following the manufacturer’s instructions. Purity greater than 90% was deemed 
acceptable. EGFP+ cells were isolated from tumors and peritoneal lavage using flow 
cytometry. Purity of the obtained cells was checked after sorting by reanalyzing the 
relevant fraction on the same instrument after a full cleaning protocol. 
Isolation of Bone Marrow Neutrophils 
Mouse neutrophils were isolated from the bone marrow of naïve mice. Ly6G+ cells 
were isolated by using an APC conjugated anti-Ly6G antibody (clone 1A8) and anti-APC 
microbeads with MiniMACS columns (Miltenyi Biotec, Bergisch Gladbach, Germany) 
following the manufacturer’s instructions.  The murine neutrophil isolation protocol 
routinely yields cell suspensions that are >85% neutrophils. All of the neutrophil studies 
were carried out at 37 °C. 
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Immunohistochemistry 
Animals bearing flank tumors were euthanized and the tumors were immediately 
placed in Tissue-Tek OCT compound (Sakura Finetek Inc., Torrance, CA) to be stored at 
−80°C, followed by sectioning. Frozen sections (8 µm) were dried in air, hydrated with 
PBS, blocked with 1 % BSA and anti CD16/32 Fc blocker (1:500 v/v) in PBS (containing 
0.1 % Triton X-100) for 30 min followed by incubation with primary antibodies for 1 hr at 
room temperature (RT). Sections were washed three times in PBS followed by incubation 
with corresponding secondary antibodies for 1 hr. After washing in PBS, sections were 
treated with 4´, 6-diamidino-2-phenylindole (DAPI) for 10 min to stain nuclei, washed 
twice and mounted with anti-fade reagent (Thermo Scientific).   
To prepare paraffin tissue sections, tumor tissues were immersion-fixed in 4% PBS-
buffered formalin, embedded in paraffin, sectioned, and stained with H&E using standard 
techniques.  
Quantitative analysis of vessels was done using the ImageJ Software 
(http://rsbweb.nih.gov/ij/). For each sample, CD-31-positive microvessels were counted in 
five x100 microscopic fields randomly selected within viable tumor areas.  
In situ analysis of tumor proliferation and apoptosis 
To determine the proliferative and apoptotic states of tumors, phosphohistone H3 
and caspase-3 staining, respectively, was performed on paraffin-embedded tumor sections. 
The number of apoptotic or proliferative cells in a given field (0.8×0.6 mm) was counted 
for quantitative analysis. Several discrete sections were examined for each tumor. Tumors 
from five different animals were examined for each experimental group of mice. 
Quantitative analysis of apoptotic and mitotic cells were done using the ImageJ software. 
Immunoassay for TGF-β 
The concentrations of TGF-β1 in peripheral blood plasma of treated, untreated and 
naïve (non-tumor bearing) mice were measured using an ELISA kit, employing the 
quantitative sandwich enzyme immunoassay technique (Quantikine, R&D Systems) 
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Briefly, blood samples were collected in heparin coated collection tubes (BD, 
Microtainer) by cardiac puncture at the time of euthanasia. To extract plasma, blood 
samples were centrifuged for 20 min at 1000 x g. Plasma was collected from supernatants 
and centrifuged at 10.000 x g for 10 min for complete removal of platelets. Plasma samples 
were assayed for TGF-β1 by following the manufacturer’s instructions.  The absorbance 
was recorded using a SPECTRAmax GEMINI XS microplate reader (Molecular Devices) 
at 450-nm wavelength. The ELISA for TGF-β1 included acidification and neutralization 
steps resulting in measurement of total TGF-β1 (both active and latent forms). 
Quantitative RT-PCR 
For quantitative RT-PCR, total RNA was extracted from sorted cells or tumors 
using RNeasy Kit (Qiagen, Valencia, CA) and reverse-transcribed with the Omniscript 
reverse transcriptase kit (Qiagen). Primers for TNF-α, IFN-γ, IL-12, arginase-1, CD163, 
TGF-β1, MHC-class II, CXCL1, CXCL5, CXCL2 and CCL3 were designed using primer 
design software. Predesigned, validated primer sets for IL-10 and iNOS were purchased 
from Origene (Rockville,MD). Real time PCR was performed on a Light Cycler 480 
instrument (Roche Diagnostics) using SYBR Green PCR master mix. PCR settings were: 
95ºC, 5 min, 45 cycles of 10 s 95ºC, 25 s annealing and 15 s 72ºC. The same cycling 
parameters were used for all primer sets. Primers were purchased from Microsynth 
(Switzerland) and Origene (Rockville, MD). Gene specific primer sequences and annealing 
temperatures are given in Table S1. Reactions were performed in triplicates for each 
sample. Single gene products were obtained for all reactions as assessed by melt curve 
analysis or gel electrophoresis. The quantity of target mRNA was normalized to GAPDH 
and β-Actin levels in each sample.  Fold changes were calculated using the Pfaffl 
equation257 and relative changes in gene expression were calculated using 2(-Delta Delta 
C(T)) method227.  
In vitro assays of CD8+ T cell proliferation and activation 
Splenic CD8+ T cells from naïve mice were isolated using negative selection via 
MACS separation, according to the CD8+ T cell isolation kit II (Miltenyi Biotec). GFP+ 
myeloid cells were isolated using FACS sorting. For the CFSE proliferation assay, splenic  
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CD8+ T cells from naive mice were incubated for 5 min in the dark with 5 μM CFSE in 
PBS and then washed two times. The assay was performed in 200 μl RPMI 1640 complete 
medium in 96-well round bottom plates. A total of 3x104 GFP+ cells were cultured with 
CFSE-labeled 1×105 CD8+ T cells (ratio 1:3) and incubated at 37°C in 5% CO2 for 72 h.  In 
vitro IFN-γ production and CFSE proliferation of CD8+ T cells were measured by using 
CyAn ADP flow cytometer and analyzed with FlowJo Software (Tree Star).  
In vitro migration assay 
GFP expressing neutrophils were isolated from bone marrow of MacGreen mice by 
using APC conjugated anti-Ly6G antibody and subsequent anti-APC microbeads with 
MidiMACS LS columns (Miltenyi Biotec, Germany) following the manufacturer’s 
instructions. Sort-purified cells were then cultured in media (DMEM-2.5%FCS, G-CSF 
100ng/ml, M-CSF 5ng/ml) supplemented with 2.5 or 5 μg/ml anti-TGF-β antibody (clone 
1D11, R&D) or its isotype control for 16 hours. These cells were then collected, washed 
and tested for migration ability.  
Cell migration was assayed using Fluoroblok Transwell chambers containing 3μΜ 
pore-size membranes in 24 well plates (BD biosceinces). The lower chamber was filled 
with 700 μl conditioned medium from LLC cells treated with or without zoledronate at 
concentration of 10 μΜ. Neutrophils (1x105) previously treated with different 
concentrations of TGF-β inhibitor antibody were suspended with 250 μl medium (DMEM-
2.5%FCS) seeded to the upper chamber. After 4 hours, percentage of migrating cells was 
scored by measuring the intrinsic GFP signals emitted by neutrophils on the undersurface 
of the polycarbonate membranes.   
Preparation of zoledronate liposomes 
Liposomes composed of soy phosphatidylcholine (SPC, 100 mg/ml), cholesterol (10 
mg/ml) and D,L-α-tocopherol (0.2 mg/ml) corresponding to 1:0.2:0.01 mol parts were 
prepared by freeze-thawing and filter extrusion. The dry lipid mixture was solubilized in a 
physiologic phosphate buffer (20 mM, pH 7.4) supplemented with mannitol (230 mM, PB-
Man) as cryoprotectant, allowing freezing of the liposomes, and 4 mg/ml zoledronate (2-
(imidazol-1-yl)-hydroxy-ethylidene-1,1-bisphosphonic acid disodium salt, 4.75 hydrate,  
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C5H10N2O7P2  4.75 H2O, molecular weight: 401.6, Novartis Pharma AG, Switzerland). The 
resulting multilamellar vesicles were freeze-thawed in 3 cycles of liquid nitrogen and water 
at 40ºC, followed by repetitive (5-10x) filter extrusion through 400 nm and 100 nm 
membranes (Nuclepore, Sterico, Switzerland) using a Lipex extruder (Lipex 
Biomembranes, Inc., Canada). Non-encapsulated zoledronate was removed by dialysis 
(Spectrapore tube, 12-14.000 mol. Wt. cut-off) with PB-Man as dialysis buffer (1:100 v/v). 
All preparations were sterile filtered through 0.45 µm filters (Pall Gelman Laboratory) and 
aliquots of 0.05 to 0.1 ml stored at -80ºC. Liposomes containing 14C-labelled zoledronate 
(specific activity 7.07 MBq/mg, obtained from Novartis) were prepared accordingly by 
trace labeling. Liposome size and homogeneity were routinely measured with a Nicomp 
laser light scattering particle sizer (Nicomp 370, Sta. Barbara, CA). Zoledronate liposomes 
contain approximately 1.25 mg/ml zoledronate. Control liposomes were prepared 
accordingly, except for the addition of zoledronate. Both types of liposome formulations 
have a mean diameter of 135±70 nm.  
Determination of 14C-zoledronate distribution in LLC tumor bearing mice 
Organ and tumor distribution was essentially done as described by Marty et al.258 
Mice received 3 x 105 LLC cells s.c. on both sides of the flanks. As tumors had reached 
sizes of approximately 0.5 cm in diameter, radiolabeled free zoledronate or zoledronate 
liposomes were injected i.v. After 24 h the animals were anaesthetized and sacrificed by 
heart puncture and blood, lung, liver, spleen, kidneys, bone (femur and tibia) and tumors 
were removed, weighed, solubilized in Soluene-350 (Perkin Elmer, Shelton, CT, USA) and 
the radioactivity measured by scintillation counting using Ultima Gold XR (Perkin Elmer) 
liquid scintillation cocktail with a TriCarb liquid scintillation system (PerkinElmer) Blood 
correction factors were applied to all organ samples.259 Experiments were done by R. 
Schwendener. 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5.02 software (GraphPad 
Software, Inc.). Values are expressed as mean ± SEM. Statistical comparisons were made 
using the two-tailed Student’s t-test for single value comparisons or one-sample t-test and  
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2-way ANOVA for comparisons of 3 or more groups. Differences were considered to be 
statistically significant when p<0.05. 
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7. LIST of ABBREVIATIONS 
 
Ab: Antibody 
ANT: Adenine nucleotide translocase 
ATP: Adenosine triphosphate 
bFGF: Basic fibroblast growth factor 
BMP: Bone morphogenic protein 
CCL2: Chemokine C-C motif ligand 2 
CIS: Carcinoma in situ 
CML: Chronic myeloid leukemia 
COX-2: Cyclo-oxygenase 2 
CSF-1: Colony stimulating factor 
CSFE: 5,6-carboxyfluorescein diacetate succinimidyl ester 
GGPP: Geranylgeranyl pyrophosphate 
EGF: Epidermal growth factor 
H&E: Haematoxylin and Eosin 
FGF: Fibroblast growth factor 
FPP: Farnesyl pyrophosphate  
HIF-1:Hypoxia inducible factor 
HRG: Histidine-rich glycoprotein 
iNOS: Inducible nitric oxide synthase 
IFN-γ: Interferon gamma 
IHC: Immunohistochemistry 
LLC: Lewis lung carcinoma 
LPS: Lipo-polysaccharide 
M1: Pro-inflammatory macrophages, M1 phenotype 
M2: Pro-tumor macrophages, M2 phenotype 
Mac 1: Macrophage antigen 1 
MDSCs: Myeloid-derived suppressor cells 
MCP-1: Monocyte chemotactic protein-1 
MMP: Matrix metalloproteinase 
MPS: Mononuclear phagocytic system 
MVD: Mean vascular density 
N1: Pro-inflammatory neutrophils, N1 phenotype 
N2: Pro-tumor neutrophils, N2 phenotype 
N-BPs: Nitrogen-containing bisphosphonates 
NFκb: Nuclear factor-κb  
PTHrP: Parathyroid hormone-related peptide 
PDGF: Platelet derived growth factor 
PlGF: Placenta growth factor-1 
PPi: Pyrophosphate analogs 
PyMT: Polyoma middle-T-oncogene 
RANKL: Receptor activator of nuclear factor kappa-B ligand 
RES: Reticuloendothelial system 
ROS: Reactive oxygen species 
rTGF-β: Recombinant transforming growth factor-beta 
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SDF-1: Stromal derived factor-1 
SHIP1: SH2 (Src homology 2)-containing inositol phosphatase-1 
SRE: Skeletal related events 
STAT: Signal transducers and activators of transcription 
TAM: Tumor associated macrophage 
TGF-β: Transforming growth factor-beta 
TILs: Tumor infiltrating leukocytes 
TNF-ά: Tumor necrosis factor-alpha 
Tregs: T-regulator cells  
uPA: Urokinase-type plasminogen activator 
VEGF: Vascular endothelial growth factor 
VEGFR1: Vascular endothelial growth factor receptor 1 
Zol: Zoledronate (administered in the free form) 
Zoledrolip: Liposome encapsulated zoledronate 
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8. APPENDIX 
 
 
Supplementary Figure S1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1:Effect of zoledronate on MC38 tumor angiogenesis. MC38 tumors excised from 
zoledronate treated and untreated animals were embedded in paraffin, sectioned, and subjected to 
immunofluorescent staining with anti-CD31.Diagrams depict mean numbers of vessels per field 
±SEM (×100 magnification). Microvessels were counted in five randomly selected fields of tumors 
from four mice of each group. 
 
 
 
Supplementary Figure S2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2: Infiltration of LLC tumors with myeloid cells. LLC tumors from treated and 
untreated MacGreen mice were removed, paraffin embedded, sectioned and stained for CD163 
(red), GFP (green) and DAPI (blue). IHC analysis revealed that although the frequency of myeloid 
cells (green) increase, the abundance of CD163+ cells decrease in treated tumors.  
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Supplementary Figure S3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Effect of zoledronate treatment on abundance of myeloid  cells in spleen, blood and 
bone marrow of LLC bearing mice. Spleen, blood and bone marrow samples were harvested from 
treated and untreated animals.  Single cells suspensions were prepared as described in Material and 
Methods, stained and analyzed by flow cytometer. Spleen and blood samples from treated mice had 
a significantly higher percentage of  CD11b+ Ly6G+ neutrophils compared to untreated controls. 
Experiments were done twice with at least 5 mice per group. Data represents ±SEM. 
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Supplementary Figure S4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Efficient depletion of blood neutrophils by monoclonal α-Ly6G antibody,1A8. The 
Ab was administered as described in Materials and Maethods section. Blood samples were collected 
24 hours after the last treatment by cardiac puncture. Cell depletion was confirmed by flow 
cytometry. 100 μg of purified antibody led to more than 90% depletion of Ly6G neutrophils in 
comparison to isotype control (rat IgG2b). 
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Supplementary Table 1. Sequences and annealing temperatures of primers used for real-
time RT PCR are shown. 
 
Name of 
primer Sequence (5´-3´) 
Annealing 
temperature
CAG GTT GTC TCC TGC GAC TT GAPDH 
 CCC TGT TGC TGT AGC CGT A 55 ºC 
CTC TTC CAG CCT TCC TTC CTG β-actin GAA GCA TTT GCG GTG GAC GAT 59 ºC 
CCT CCT GGC CAA CGG CAT GG TNF-ά AGG GGT GTC CTT GGG GCA GG 59 ºC 
TCAAGTGGCATAGATGTGGAA IFN-γ CACTCGGATGAGCTCATTGA 56 ºC 
GAA GAA AGT GGT GCC ATG GAT AG  Arginase1 CCC ATG AGT TCC ATG CTC AGA 59 ºC 
IL-12 Origene, MP206746 62 ºC  
iNOS Origene, MP208933 64 ºC 
IL-10 Origene, MP206737 62 ºC 
ATG GGT GGA CAC AGA ATG GTT CD163 CAG GAG CGT TAG TGA CAG CAG 58 ºC 
CCC CAC TGA TAC GCC TGA GT TGF-β AGC CCT GTA TTC CGT TCT CTT 57 ºC 
CCAGGAGGACCTTGTGTGAT VEGF GGGAAGGGAAGATGAGGAAG 57 ºC 
GGC TCC TCA AGC GAC TGT GT MHC-
classII GGG GCT GGA ATC TCA GGT TC 58 ºC 
CCG AAG TCA TAG CCA CAC TCA A CXCL1 GCA GTC TGT CTT CTT TCT CCG TTA C 59 ºC 
GGT CCA CAG TGC CCT ACG CXCL5 GCG AGT GCA TTC CGC TTA 59 ºC 
GAG CTT GAG TGT GAC GCC CCC AGG CXCL2 GTT AGC CTT GCC TTT GTT CAG TAT C 60 ºC 
ACC ATG ACA CTC TGC AAC CA CCL3 TCA GGC ATT CAG TTC CAG GT 60 ºC 
 
                                                                                                     ACKNOWLEDGEMENT 
 118
 
9. ACKNOWLEDGEMENT 
 
Fist of all, I would like to thank Prof. Dr. Reto Schwendener for giving me the 
opportunity to do my Ph.D. in his lab and for the stimulating suggestions and 
encouragement helped me in all the time of research and writing of this thesis. He is always 
available for consulting and discussing any problems that I had, and has given me the 
freedom to pursue the project without objection.  
Furthermore, I would like to express my gratitude Prof. Josef Jiricny for giving me 
the opportunity to join the IMCR and for the financial support during the first two years of 
my PhD. 
I sincerely thank the members of my Ph.D. committee, Professors Anne Müller, 
Sabine Werner, Alessandro  Sartori and Lubor Borsig for their time, valuable comments 
and suggestions in general. Special thanks to Prof. Müller for agreeing to be my 
“Dissertations Leiterin” and also to her laboratory members for mutually beneficial 
exchange of knowledge and resources. Thanks also to PD. Dr. Borsig for providing us with 
the cell lines and organizing the tumor immunology journal clubs that involved a lot of 
useful discussions. 
My special thanks go to Dr. Sushil Kumar who has actively participated in this 
work. I am greatly benefited by his scientific input, discussion and suggestions. I've learned 
a lot from him during the past three years. Furthermore, when things got tough, he was 
there to listen and advise. I also thank Dr. Anne-Katrine Bonde for scientific and private 
discussions and offering me help, coffee and dinner whenever needed.  
I also thank to my dear colleague and friend soon to be Prof. Ayca Sayi. She is a 
wonderful and generous friend. I know that I could always ask her for advice and opinions on 
lab related as well as private issues. I’ll never forget the many cheerful lunches and all other fun 
activities we’ve done together. 
Next, to my dearest friends, Çiğdem Efeoğlu, Nilüfer Telli, Gül Fidan Sarıbay and 
Erhan Astarcı, a big heartfelt thank you for the encouragement during tough times in the 
Ph.D. pursuit and for providing me the needed balance and perspective on life outside of 
graduate school. 
 
                                                                                                     ACKNOWLEDGEMENT 
 119
My sincere appreciation goes to all IMCR members: friends, colleagues, 
administrative, technical and maintenance staff who have created such supportive and 
collaborative working environment. 
I gratefully acknowledge the funding sources that made my Ph.D. work possible. I 
was funded by the internal sources of IMCR for my first 2 years and was then supported by 
a Novartis grant for years 3 & 4.  
Finally, special recognition goes out to my parents, Muhsin and Solmaz Mete, for 
all the unwavering support, unconditional love and constant encouragement they have 
always given me throughout my whole life and for making me who I am today. This 
achievement would have been impossible without your support. I am also particularly 
grateful for the love and support of the rest of the close family: my brother Tarık Mete, 
sister in law Selcen Mete and my little angel, Asya Mete. 
 
 
 
 
 
 
[ / 1] 120
CURRICULUM VITAE 
PERSONAL DETAILS 
Surname:       METE 
     Name:       Sibel 
                            Birth date and place: 
                                             Citizenship: 
November 2nd, 1977 – Ankara 
Republic of Turkey 
EDUCATION 
Since 2007  Ph.D. student, University of Zurich, Institute of Molecular Cancer Research at University of Zurich 
Switzerland 
Doctorate  Dissertation:  Zoledronate  mediated  modulation  of  tumor  microenvironment  leads  to 
impaired tumor growth 
2000 – 2003  Master’s Degree  in Biotechnology, Department of Biotechnology, Graduate School of Natural and 
Applied Sciences, Middle East Technical University, Ankara, Turkey 
 
Master  Thesis:  Scytalidium  thermophilum  Polyphenol  Oxidase:  Production  and  Partial 
Characterization 
  
1995 – 1999 
1991 – 1995 
 
Bachelors Degree in Biology, Department of Biology, Faculty of Science, Ankara University, Turkey  
High School, Fatih Sultan Mehmet Lisesi, Turkey 
PUBLICATIONS 
1. Ogel ZB, Yuzugullu Y, Mete S, Bakir U, Kaptan Y, Sutay D, Demir AS. (2006) Production, Properties and      
Application to Biocatalysis of a Novel Extracellular Alkaline Phenol Oxidase from Thermophilic Fungus 
Scytalidium thermophilum, Applied Microbiology and Biotechnology, Aug;71(6):853‐62 
2. Mete  S,  Kumar  S,  Schewendener  R.  (2011)  Zoledronate Nanoparticules  Repolarized Neutrophils  In 
Tumor  Microenvironment  to  Counteract  Tumors  which  are  Refractory  to  Anti  Angiogenic  Drugs, 
manuscript in preparation 
PROFESSIONAL EXPERIENCES 
                Since 2007      Employed as Post Graduate Student, Institute of Molecular Cancer Research, University of Zurich 
                  1995 – 1999     Employed as Specialist Researcher, Molecular Biology Biotechnology research and Development  
                                             Center, Middle East Technical University, Turkey  
                  1995 – 1999     Employed as Biologist, Environmental Protection Agency for Special Areas, Ministry of Environment, 
                                             Turkey 
LANGUAGES 
English:  Fluent 
 
                            German:  Basic  
 
                             Turkish:   Native 
 
